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Silver nanoparticles (AgNPs) are widely used in consumer products and the medical field 
for their antimicrobial properties. Some studies reported toxic effects of AgNPs but cellular uptake 
of AgNPs and AgNP-induced inflammation pathways are still not fully understood. Mast cells and 
macrophages are essential players of innate and adaptive immune response against invading 
foreign materials. Mast cells and macrophages express various receptors to help in recognition and 
clearance of invading pathogens and foreign molecules. Scavenger receptors such as scavenger 
receptor B1 (SR-B1) expressed by different types of cells, play an important role in biomolecule 
transport such as cholesterol transport inside cells. In addition, SR-B1 has been reported to be a 
multi-ligand receptor and can interact with negatively charged molecules leading to uptake and 
activation of signaling pathways. The aim of this study was to investigate role of SR-B1 and 
influence of physicochemical properties of AgNPs on mast cell and macrophage AgNPs uptake 
and subsequent inflammatory responses. We assessed mast cell and macrophage uptake of 
different types of AgNPs that differ in shape, size, charge, coating, and suspension media. The 
physicochemical properties were found to influence levels of AgNPs uptake by mast cell and 
macrophage. In addition, inflammatory responses of mast cells and macrophages were found to be 
influenced by the physicochemical properties of AgNPs. Furthermore, SR-B1 was found to 
mediate AgNPs cellular uptake and influence the inflammatory response following AgNPs 
exposure.  
These findings have implications in understanding mechanisms of AgNPs toxicity. Further, 
these findings suggest that modifications of the physicochemical properties can help in targeting 
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CHAPTER 1: INTRODUCTION 
Nanoparticles 
Nanotechnology is a fast-developing field that includes the production and use of 
nanoparticles (NPs). NPs are defined as particles that have at least one dimension between 1-100 
nanometers (nm). Nanotechnology is expected to reach 1 trillion $US with more than 1,800 
consumer products introduced to the market by 2015 compared to 54 products in 2005 (Vance et 
al., 2015). Due to their small size, NPs exhibit unique properties that differ from their bulk form. 
These properties include physical and chemical properties such as high tensile strength, low 
weight, and electrical conductivity which leads to increased use of NPs in different products such 
as paints, cosmetics, food storage, and nanomedicines (Ma et al., 2008, Vance et al., 2015). 
Silver nanoparticles (AgNPs) are one of the most widely produced and used NPs due to 
their broad-spectrum antimicrobial properties (Levard et al., 2013, Dong et al., 2012).  Currently, 
AgNPs can be found in more than 400 consumer products such as water filters, cosmetics, wound 
dressings, toothpaste and household products which make them the most popular type of NPs 
(Marambio-Jones and Hoek, 2010, Vance et al., 2015). This increase in use of AgNPs products 
raises concern of its effects on environmental and human health (Varner et al., 2010, Luoma, 2008, 
Levard et al., 2012, Liu et al., 2012, Reidy et al., 2013, Sharma, 2013, Stevenson et al., 2013, 
Unrine et al., 2012, Yu et al., 2013b, Wijnhoven et al., 2009). 
Factors Affecting NPs Toxicity 
The toxic effects caused by NPs can be influenced by different factors that should be 
measured and characterized to ensure sustainability and safe use of NPs. First, variation in size of 
2 
 
NPs can modulate the level of cellular uptake or interaction with biological systems (Nel et al., 
2006). The smaller size of the particle has more biological activity and toxicity due to their ability 
to reach and translocate easier than larger particles in biological systems (Oberdörster et al., 2005). 
Second, surface area of the NPs is another important factor in which reduction in size of particles 
to the nanoscale leads to a significant increase in the surface to volume ratio resulting in an increase 
in the number of particles per mass unit that are exposed to tissues or cells (Warheit, 2004). Third, 
NPs can be found in different shape such as spheres, tubes, and needles. The shape of NPs can 
affect their mobility, diffusion, deposition, and adsorption kinetics in biological systems (Park et 
al., 2003, Radomski et al., 2005, Jia et al., 2005, Seaton and Donaldson, 2005). Fourth, chemical 
composition of NPs can affect their biological activity. NPs can be found as inorganic such as 
metal or metal oxides, or organic such as fullerenes. In addition, some NPs can be found as hybrids 
such as quantum dots where the core consists of metalloid crystalline and an inorganic outer shell 
(Hardman, 2006). Also, chemical purity of NPs can affect biological interaction with the NPs such 
as presence of Fe or Ni as contaminants found within carbon nanotubes which are left over from 
the synthesis process (Maynard et al., 2004, Pulskamp et al., 2007, Jia et al., 2005, Bianco et al., 
2007). Fifth, surface chemistry can influence aggregation of NPs. The increase in surface to 
volume ratio increases interparticle attraction by London and van der Waals forces, and 
electrostatic interactions (Werth et al., 2003). Coating of NPs is a method to stabilize NPs and to 
prevent aggregate formation by adding surface groups such as -–COOH, and –OH (Dutta and 
Hofmann, 2004). Adding these surface groups can impact the toxic effect of the NPs and their 
behavior in the biological media (Sayes et al., 2004, Sayes et al., 2006, Borm et al., 2006, Knaapen 
et al., 2002, Schins et al., 2002, Yin et al., 2005). Sixth, surface charge of NPs due to formation of 
an electric charge when dispersed in media can influence toxicity (Cosgrove, 2010). This charge 
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can control the reaction of the NPs with cells such as phagocytosis, and the adsorption of 
biomolecules and ions (Powers et al., 2006, Schins et al., 2002, Hoet et al., 2004, Lockman et al., 
2008, Malik et al., 2000, Nigavekar et al., 2004, Quintana et al., 2002). Seventh, NPs can form 
aggregates in solution, powder, and gas phase and that depending on their size, chemical 
composition and surface charge. In addition, aggregation can depend on the production, storage, 
and handling conditions. The aggregation affects the stability of NPs suspensions and can affect 
the level of the toxic effect of NPs (Duffin et al., 2002, Wilson et al., 2002, Wick et al., 2007). 
Eighth, surface crystal defects which occur when the periodic crystalline structure of a material is 
interrupted. At defected sites, atoms tend to be more reactive than atoms at normal sites. Due to 
their large surface area, NPs tend to have more defects sites compared to bulk materials (George 
et al., 2012). The presence of surface defects was found to increase NPs toxicity through disruption 
of biomolecules via direct interaction or by increased ROS production as it has been reported that 
AgNPs with surface defects have higher toxicity on fish gill cell line and zebrafish embryos 
compared to normal AgNPs (George et al., 2012). 
Nanoparticles Protein Corona 
Upon NPs reaching a biological fluid, they are exposed to biomolecules mainly proteins 
that form a corona around the NP termed the biocorona (BC) or protein corona (PC) (Maiorano et 
al., 2010, Walkey and Chan, 2012, Cedervall et al., 2007). In addition, NPs may interact with other 
biomolecules such as sugars, nucleic acids and lipids (Wan et al., 2015, Hellstrand et al., 2009). 
The PC gives a new identity to the NPs and may carry new properties different from the original 
NP which requires investigators to re-characterize the NP after forming the PC. Over time, the 
binding or adsorption of proteins on the surface is controlled by affinity interactions of proteins to 
the NPs surface and by affinity based protein to protein interactions (Monopoli et al., 2011). The 
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PC can be classified into hard and soft based on the exchange time of its composition (Monopoli 
et al., 2011). The hard corona is the first strong bound layer of proteins and it has long exchange 
time, whereas, the soft corona is the second layer of proteins which is not directly bound to the NP 
and only needs seconds to minutes for protein exchange (Milani et al., 2012). The composition of 
the PC is unique for each NP and it depends on the physicochemical properties of NPs (Pozzi et 
al., 2014, Lundqvist et al., 2008, Deng et al., 2009, Qiu et al., 2010, Capriotti et al., 2012, Pozzi et 
al., 2015). In addition, some biological factors can influence the composition of PC such as the 
protein source e.g. plasma vs serum or animals vs humans, incubation time, temperature and pH 
of the media (Tenzer et al., 2013, Pozzi et al., 2015, Mahmoudi et al., 2013, Hajipour et al., 2014). 
By adsorption of proteins on the surface of NPs, a protein denaturation can result due to a decrease 
in thermal stability leading to conformational changes of the adsorbed proteins (Gheshlaghi et al., 
2008, Wangoo et al., 2008, Deng et al., 2011). The toxic effects of NPs could be increased after 
formation of PC which increases internalization of NPs by phagocytic cells such as macrophages 
(Saptarshi et al., 2013). 
Importance of AgNP Physicochemical Properties in Toxicity 
Due to their antimicrobial activity, AgNPs are the most widely used NP on the market 
which led to increased concern of the potential for the release of AgNPs into the environment and 
its effects on human health (Varner et al., 2010, Schluesener and Schluesener, 2013, Levard et al., 
2012, Reidy et al., 2013, Wijnhoven et al., 2009). The most common side effect caused by AgNPs 
is argyria where the skin turned to a bluish color (Wadhera and Fung, 2005, Lansdown, 2004). 
Some studies have reported different types of toxicities of AgNPs such as oxidative stress and 
DNA damage (Awasthi et al., 2013, Haase et al., 2012, Lim et al., 2012, van Aerle et al., 2013, 
Johnston et al., 2010). The AgNPs undergo different transformations in the environment and 
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biological system that depend on the type of preparation of AgNPs, types of surface coating, and 
environmental conditions, (Kruszewski et al., 2011, Cunningham et al., 2013, El Badawy et al., 
2010, George et al., 2012, Kim et al., 2013, Levard et al., 2013, Liu et al., 2010). 
When AgNPs are introduced into biological media, the NPs undergo physical and chemical 
changes.  This includes losing or displacing the surface coating. Surface coating agents such as 
citric acid, polyvinylpyrrolidone (PVP) or amino acids are attached to the AgNPs by noncovalent 
bonding in an equilibrium state and are used to maintain stability and solubility of the AgNPs. 
When AgNPs are dispersed in the biological medium, the surface coating undergoes the process 
of reestablishing equilibrium by losing some coating molecules or displacing the surface coating 
agent itself with other biological molecules or ions which resulted in a change in AgNPs stability 
(He et al., 2012a, George et al., 2012, Li et al., 2013b). Additional changes that occur include 
alteration in the aggregation and agglomeration state of the NPs. Losing or displacement of the 
surface agents leads to instability of the NPs and results in aggregation (Li et al., 2013b, Meyer et 
al., 2010). Another critical change is the release of silver ions after surface oxidation. The presence 
of silver atoms on the surface of AgNPs leads to interactions with oxygen molecules to produce 
silver oxide which can interact with redox active compounds to produce silver ions which can take 
place in biological media or inside the cell (Reidy et al., 2013, Yang et al., 2011, George et al., 
2012, Kim et al., 2013, Liu et al., 2010, Ahamed et al., 2008, Bae et al., 2011, Bilberg et al., 2011). 
The transformation of AgNPs in biological media has also been reported to be influenced by the 
presence of sulfur ions, sulfur-containing compounds, dissolved oxygen, chloride ions, and light 
(Levard et al., 2012, Liu et al., 2012, Cunningham et al., 2013, Levard et al., 2013, Li et al., 2013b, 
Lankveld et al., 2010, Lee et al., 2007, Liu et al., 2011). 
Mechanisms of AgNP Toxicity 
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As mentioned before, silver ions released when AgNPs are introduced to biological media 
could contribute to the toxic effects of the AgNPs therefore it is important for researchers to 
distinguish between the toxic effect that is caused by AgNPs or silver ions (Beer et al., 2012, van 
der Zande et al., 2012). AgNPs have been reported to inhibit cell proliferation via activating 
different signaling pathways after interacting with cell membrane proteins (Braydich-Stolle et al., 
2010, Asharani et al., 2008b, Asharani et al., 2009, Gopinath et al., 2010). In addition, cellular 
uptake of AgNPs has been reported to cause mitochondrial dysfunction, and protein and DNA 
damage due to reactive oxygen species (ROS) generation (Haase et al., 2012, Roh et al., 2012, van 
Aerle et al., 2013, Li et al., 2013b, He et al., 2012b, Bressan et al., 2013, Chairuangkitti et al., 
2013, Ahmadi and Branch, 2012, Carlson et al., 2008). Another reported toxicity mechanism of 
AgNPs and silver ions is their interaction with biomolecules that have sulfur or cysteine residues 
such as proteins (Ahamed et al., 2008, Lee et al., 2007, Choi et al., 2009, Asharani et al., 2009, 
Banerjee and Das, 2013, Kaur and Tripathi, 2011, Hou et al., 2013). The NP-protein interaction 
can modify the structure and the function of the adsorbed protein resulting in conformational 
changes in the structure of adsorbed protein as it has been reported in different studies conducted 
on different types of NPs such as gold NPs, titanium dioxide (TiO2)  NPs, and iron oxide NPs 
(Wangoo et al., 2008, Gheshlaghi et al., 2008, Mahmoudi et al., 2011). AgNPs found in different 
studies to interact with different types of proteins such as bovine serum albumin (BSA) and human 
serum albumin (HAS) and that resulted in induced and increase in the protein conformational 
entropy and decrease in α-helix content (Treuel et al., 2010, Treuel et al., 2012, Shannahan et al., 
2013b, Gebauer et al., 2012, Chen et al., 2012b). 
AgNPs have been reported to accumulate outside the mitochondria causing damage that 
disturbs the function of the respiratory chain leading to ROS generation and oxidative stress 
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(Bressan et al., 2013). In addition, the mitochondrial damage caused by AgNPs can lead to ROS 
generation and interrupt ATP synthesis which results in DNA damage (AshaRani et al., 2008a). 
Another study reported that AgNPs induced apoptosis in fibroblasts through ROS generation and 
C-Jun pathway activation which resulted from increased cytochrome c production (Hsin et al., 
2008). Apoptosis can also be induced by AgNPs through G1 arrest and S phase block (Park et al., 
2010). 
The antimicrobial activity of AgNPs has been reported to be due to an interaction of AgNPs 
with bacterial membrane, penetration, and accumulation in cells and causing cytoplasm damage 
or binding to the DNA (Wigginton et al., 2010, Khan et al., 2011a, Khan et al., 2011b, Grigor’eva 
et al., 2013). In different types of mammalian cells, AgNPs have been reported to cause membrane 
damage, altering membrane permeability, apoptosis due to oxidative damage, increase calcium 
influx, reduce in mitochondrial membrane potential and reduce in cell viability (Baruwati et al., 
2013, Chairuangkitti et al., 2013, Cheng et al., 2013). 
AgNPs can be taken up and internalized by different type of cells and can be dependent on 
the size, shape, or incubation time (Yu et al., 2013a, Locht et al., 2011, Lu et al., 2010, Miao et al., 
2010, Choi and Hu, 2008, Meyer et al., 2010). Different studies reported comparison of the AgNPs 
uptake by different types of cells at different concentrations, time points, and different coating 
including PC. These studies demonstrated the influence of physicochemical properties on cellular 
uptake and the resulting toxic effects (Haase et al., 2012, Kruszewski et al., 2011, Meyer et al., 
2010, Choi and Hu, 2008, Miao et al., 2010, Yu et al., 2013a, Kruszewski et al., 2013, Monteiro-




Mast cells are derived from CD13+CD34+CD117+ (also known as c-Kit) hematopoietic 
stem cells  in the bone marrow (Metcalfe et al., 1997). Developing mast cells migrate to different 
tissues such as the skin and airways then differentiate in the presence of stem cell factor (SCF) 
which is a ligand for the c-Kit receptor (Brown et al., 2008b). In addition to SCF, several mediators 
contribute in mast cell growth and differentiation such as IL-3, IL-4, IL-6, IL-9, IL-10, nerve 
growth factor (NGF), Prostaglandin E2 (PGE2), α4 integrins, and vascular cell adhesion molecule-
1 (VCAM-1) (Wiener et al., 2004, Brown et al., 2008a, Abonia et al., 2006, Hallgren et al., 2007). 
Mast cells can survive for months or years and can proliferate in response to appropriate signals 
(Abraham and Malaviya, 1997, Padawer, 1974). Mast cells are found in most tissues such as brain, 
heart, lymph nodes and are mainly located at the host’s interface with the environment such as 
skin and mucosa as they play an important role in the recognition of pathogens such as parasites 
and bacteria (Woodbury et al., 1984, Nawa et al., 1985, Yong, 1997, Ghanem et al., 1988, Weidner 
and Austen, 1991). Mast cells rapidly respond to environmental stimulation by degranulation and 
release of their preformed mediators, such as histamine, serotonin, and proteases as protective 
immune response and can synthesize de novo mediators including leukotrienes, prostaglandins, 
and cytokines to help promote adaptive immune responses (Brown et al., 2008a). Mast cells and 
their mediators are best known for their association with different pathological conditions such as 
asthma, allergy, and anaphylaxis (Brightling et al., 2002, Patterson and Suszko, 1971, Metcalfe et 
al., 2009). In addition, due to the presence of mast cells in different types of tissues, mast cells 
have been reported to contribute to different pathophysiological conditions in organs such as the 
brain and the cardiovascular system (Wilhelm et al., 2005, Zhuang et al., 1996, Bot et al., 2007, 
Dvorak, 1986, Ghanem et al., 1988, Gilles et al., 2003). 
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Paul Ehrlich in 1879 was the first to discover and describe the mast cell and named it as 
mastung (i.e. overfed) cells where their cytoplasmic granules showed a strong purple-red 
metachromasia after staining with methylene or toluidine blue (Ehrlich, 1879, Beaven, 2009). Mast 
cells are highly heterogeneous cells and can be found in different phenotypes (Abe et al., 1990, 
Vliagoftis and Befus, 2005). The heterogeneity of mast cells can be shaped based on the specific 
type of the host tissue or to the type of the invading pathogen (Abraham and John, 2010). Based 
on staining properties of their granules, rodent mast cells can be categorized into mucosal or 
connective tissue mast cell types (Abraham and John, 2010). Further, these two categories can be 
distinguished by several properties including granules composition, degranulation response to 
stimulation, and their proliferation ability (Metcalfe et al., 1997). Proteases are the main protein 
components of mast cell granules (Metcalfe et al., 1997). Tryptases and chymases are the protease 
components of mouse connective tissue mast cells granules and can be found to contain heparin 
(Metcalfe et al., 1997). Mouse mucosal mast cell granules contain only chymases and can be found 
to contain chondroitin sulphate (Metcalfe et al., 1997). Human mast cells can also be differentiate 
based on the protease types into mast cell containing only tryptase (MCT) and mast cell containing 
both tryptase and chymase (MCTC) (Welle, 1997, Irani et al., 1986). In addition to proteases 
content, human mast cells can be classified based upon their expression of complement component 
C5a receptor (C5aR)(CD88) (Oskeritzian et al., 2005). Mast cell protease content varies not only 
between mast cell subtypes but also within individual mast cells depending on the type of stimulus 
as it has been reported that protease expression levels can be modulated by IL-10 and IL-4 
(Ghildyal et al., 1992, Toru et al., 1998). 
Mast Cell Activation by FcRs 
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Mast cells express Fc receptors (FcRs) including FcγRII receptors and FcεRI which is the 
high-affinity receptor for IgE (Brown et al., 2008a, Abraham and John, 2010). Mast cells can bind 
to both IgG and IgE and become sensitized to antigens that have been encountered previously and 
that leads to receptor cross-linking by the antigen subsequently resulting in mast cell activation 
and degranulation (Kawakami and Galli, 2002, Woolhiser et al., 2001). This type of mast cell 
activation is most studied and well characterized in models of asthma and allergy. When FcεRI is 
crossed linked with the antigen-antibody complex, signaling events started by phosphorylation of 
FcεRI cytosolic domains, immunoreceptor tyrosine-based activation motifs (ITAMs), activation 
of phosopholipase C (PLC) resulting in the initiation of calcium signaling within the endoplasmic 
reticulum through store-operated calcium channels as well as an influx of extracellular calcium 
which leads to degranulation of mast cell (Metcalfe et al., 2009). Activation of mast cells via FcεRI 
and Toll-like receptors (TLRs) at the same time leads to an increase in activity of mitogen-
activated protein kinases (MAPKs) and that results in synergistic effects on cytokine production 
by the mast cell (Qiao et al., 2006). Mast cell activation can be achieved via FcR signaling that is 
induced by bacterial superantigens such as Staphylococcus aureus protein A and 
Peptostreptococcus magnus protein L which both can bind to certain antibodies independent of 
antigen specificity (Genovese et al., 2000). 
Mast Cell Activation by Endogenous Inflammatory Factors 
Mast cell activation can be induced by different endogenous peptides such as neurotensin, 
substance P and endothelin 1 (Johnson and Krenger, 1992, Maurer et al., 2004). In addition, mast 
cells can be activated by complement components such as C5aR (Nilsson et al., 1996, Mullaly and 
Kubes, 2007).  Further, complement components C3 and C4 have been reported to activate mast 
cells and that has been demonstrated using knock out mice models (Prodeus et al., 1997). Mast 
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cells also can be activated by C3a and C5a complement proteins by initiating signaling through 
activation of G protein-coupled receptors (GPCRs) expressed on the surface of mast cells resulting 
in calcium mobilization and Nuclear factor of activated T-cells (NFAT) activation (Ali et al., 
2000). In addition, the C3 complement pathway can be activated following IgG binding to FcγRIII 
that is expressed on the surface of mast cells resulting in opsonization of pathogens and subsequent 
mast cell activation (Baumann et al., 2001). A newly recognized pathway of mast cell activation 
is through the ST2 receptor and IL-33.  Importantly, it has been reported that mast cells are 
activated through IL-33 following nanoparticle exposure. (Katwa et al., 2012, Wang et al., 2011). 
Mast Cell Activation 
Within seconds to minutes following recognition of an invading pathogen, mast cells 
release preformed mediators and are one of the first cells to respond to an invading pathogen 
(Burke et al., 2008). Following recognition, mast cells produce certain cytokines and mediators 
depending on the type of pathogen and can also replenish its granule storage during an infection 
or after resolving the infection (Metcalfe et al., 1997, Burwen, 1982). In infections, mast cells are 
responsible for recognizing the invading organism. With help of dendritic cells (DCs), epithelial 
and endothelial cells that are located in different sites such as the skin or the gut, the host immune 
system becomes alerted. Mast cells express pattern recognition receptors (PRRs) such as TLRs 
that can directly recognize pathogen-associated molecular patterns (PAMPs) and become activated 
(Trinchieri and Sher, 2007).  In addition to TLRs, mast cells express other receptors that play an 
important role in pathogen recognition such as FcRs which bind to pathogen-specific antibodies 
(Kawakami and Galli, 2002, Woolhiser et al., 2001). Based on the type of PAMPs, mast cell 
responses can vary as it has been reported that activation of TLR4 of rodent mast cells by 
lipopolysaccharide (LPS) resulted in cytokine production with no degranulation while activation 
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of TLR2 by peptidoglycan resulted in degranulation and cytokine production (Supajatura et al., 
2002). Further, the previous study reported that activation of TLR4 and TLR2 resulted in 
production of cytokines including tumor necrosis factor (TNF), IL-6, and IL-13 while IL-1β was 
produced only in TLR4 activation whereas IL-4 and IL-5 only produced following TLR2 
activation (Supajatura et al., 2002). Human mast cells also show different responses upon TLR4 
and TLR2 activation by peptidoglycan and LPS where both induced T helper2 (TH2)-type response 
while peptidoglycan alone induced histamine release but not LPS (Varadaradjalou et al., 2003). 
Mast cells can also be activated through the CD48 receptor that can detect pathogens such as 
Mycobacterium tuberculosis and Staphylococcus aureus (Malaviya et al., 1999, Munoz et al., 
2003, Rocha-de-Souza et al., 2008). 
Functions of Mast Cells in Innate Immunity 
Innate immunity is the first line of immune defense that detects pathogen-associated 
molecular patterns that induce a toxic and inflammatory response (Medzhitov and Janeway, 2000). 
The innate immune system utilizes genetic memory to recognize the molecular patterns of common 
invading pathogens (Dempsey et al., 2003). Mast cells play a main role in immune cell recruitment 
to the site of infection. In blood vessels, mast cells release various mediators such as histamine, 
TNF, vascular endothelial growth factor (VEGF) and proteases that increase vascular permeability 
and produce edema at the site of infection (Boesiger et al., 1998, Sendo et al., 2003, Heltianu et 
al., 1982). Mast cells also produce different chemokines including CC-chemokine ligand 11 
(CCL11; eotaxin) and CXC-chemokine ligand 8 (CXCL8; IL-8) that facilitate the recruitment of 
other cells such as eosinophils and natural killer (NK) cells (Burke et al., 2008). Neutrophil 
recruitment to inflamed locations following release of TNF and mast cell protease 6 (MCP6) by 
mast cells has been reported in different studies (Huang et al., 1998, Sutherland et al., 2008, 
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Biedermann et al., 2000). In addition, during viral infections, mast cells activated by virus-
associated stimuli such as polyinosinic–polycytidylic acid (polyI:C) produce different chemokines 
that induces NK cell chemotaxis (Burke et al., 2008). 
Following pathogen invasion, mast cells release products that affect pathogen activity such 
as cathelicidins which have bactericidal activity (Di Nardo et al., 2008). Furthermore, cathlicidin 
can be produced by mast cells in response to stimuli such as LPS (Di Nardo et al., 2003). Mast 
cells also help in killing bacteria following phagocytosis by releasing products such as ROS 
(Abraham and Malaviya, 1997). Mast cell products such as histamine, serotonin, and proteases 
play an important role in the process of pathogen elimination and removal from the body by 
communicating with other cells such as nerve cells and smooth muscle cells (Johnson and Krenger, 
1992, Margulis et al., 2009, Pothoulakis et al., 1998, Klimpel et al., 1995). Further, mast cells help 
in the process of pathogen clearance from tissues such as nasal mucosa by promoting mucus 
production by epithelial cells (Bischoff, 2009). 
Mast Cell Function in Adaptive Immunity 
Adaptive immunity involves the process of body recognition of a pathogen’s specific 
antigens and production of a specific response to destroy it (Dempsey et al., 2003). Adaptive 
immunity is responsible for generation of immunologic memory and regulation of host immune 
homeostasis following interactions between antigen-presenting cells and T and B lymphocytes 
(Bonilla and Oettgen, 2010). Mast cells activation results in a multitude of inflammatory cytokines 
being produced that contribute to and regulate the activation of other immune cells that are 
involved in adaptive immunity (McLachlan et al., 2003). In the infected tissues, mast cells produce 
TNF which increases E-selectin expression on local blood vessels which results in an increased 
influx of DCs (Shelburne et al., 2009). Mast cells also produce CCL20 which contributes to DC 
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precursor recruitment into the tissues (Galli et al., 2005). Furthermore, mast cells promote 
activation of epidermal Langerhans cells, a subset of DCs, following bacterial infection which 
results in increased DCs recruitment (Shelburne et al., 2009, Jawdat et al., 2006). Mast cell-derived 
histamine has been reported to modulate DC activation by promoting antigen uptake and cross-
presentation and the upregulation of co-stimulatory molecules required for T cell activation (Caron 
et al., 2001, Amaral et al., 2007). Furthermore, mast cells have been reported to promote DCs to 
acquire a TH2 cell-inducing property (Mazzoni et al., 2006). Mast cells also promote the 
recruitment of T cells as it has been reported that activation of TLR3 on mast cells leads to 
expression upregulation of CXCL10 (IP10) and CCL5 (RANTES) and an increase in CD8+ T cell 
recruitment (Orinska et al., 2005). 
Mast cells can act as antigen-presenting cells (APCs) and upregulate expression of major 
histocompatibility complex (MHC) class II and co-stimulatory molecules and they have been 
reported to interact with T cells (Metcalfe et al., 1997). Mast cells also act as APCs for MHC class 
I specific to CD8+ T cells which results in CD8+ T cell activation and proliferation that leads to in 
induced secretion of IL-2, interferon-gamma (IFN-γ), macrophage inflammatory protein-1, and 
granzyme B (Stelekati et al., 2009). 
Mast cells during infection can modulate and promote the development of adaptive 
immunity to pathogens (Shelburne et al., 2009). Mast cells in models of allergy can modulate 
adaptive immunity following binding of antibodies to FcRs and sensitization (Metcalfe et al., 
1997). In the presence of high-affinity pathogen-specific antibodies, the antibody cross-links FcRs 
on mast cells which results in a primary fast response that contributes to improving immunological 
memory formation which enhances protection against a pathogenic challenge (Metcalfe et al., 
1997, Gurish et al., 2004, Knight et al., 2000). 
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In contrast, mast cells can be modulated by T cells by physical contact between both types 
of cells or by T cell products that induce mast cell degranulation such as CCL3 (MIPIα) and CCL2 
(Mekori and Metcalfe, 1999). In addition, T cells can induce production of TNF and histamine by 
mast cells which indicates the presence of a feedback mechanism between both types of cells, and 
mast cell activity modulation by the adaptive immune system during infections (Mekori and 
Metcalfe, 1999). 
Macrophages 
Macrophages are important immune cells that play a critical role in host defense. 
Macrophages are phagocytic cells that engulf and help in removing foreign particles, pathogens, 
and cell debris. In addition, macrophages regulate organ homeostasis and play an important role 
in tissue remodeling. Macrophages are generally derived from circulating monocytes and show a 
high degree of heterogeneity which reflects the specialization of functions of macrophages in 
different anatomical locations (Gordon, 1986, Gordon, 1998). The growth and differentiation of 
macrophages depends on cytokines, such as macrophage colony-stimulating factor (M-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF), and interactions with stroma in 
haematopoietic organs (Gordon, 2003). Macrophage determination can be affected by different 
cytokines and factors such as IL-3, c-kit, TNF-family proteins, TNF-receptor related molecules, 
PU.1, and ETS-family (Gordon, 2003). Monocytes arise from common bone marrow myeloid 
progenitor cells then differentiate into macrophages under the influence of M-CSF and GM-CSF 
or into DCs under the influence of GM-CSF and IL-4 (Gordon, 2003, Alikhan and Ricardo, 2013, 
Lawrence and Natoli, 2011, Zhou et al., 2014). Monocytes distribute through the blood stream and 
enter all tissues of the body then differentiate to macrophages based on tissue-specific phenotype 
signals from the extracellular matrix and neighbor cells and their products which result in different 
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phenotypes of macrophages such as Kupffer cells in liver, alveolar macrophages in lungs, 
osteoclasts in bones, histocytes in interstitial connective tissue, and microglia in the central nervous 
system (CNS) (Gordon, 2003, Alikhan and Ricardo, 2013, Galli et al., 2011, Ricardo et al., 2008). 
Macrophage migration from the blood, endothelium, the interstitium and epithelium is controlled 
by adhesion molecules including integrins (such as β1 and β2), immunoglobulin-superfamily 
molecules (such as CD31), selectins and epidermal growth factor seven-transmembrane spanning 
(EGF-TM7)-type receptors which ae related to the F4/80(EMRI) antigen (Gordon, 2003, Stacey 
et al., 2000). The expression of macrophage genes can be influenced by cytokines such as 
transforming growth factor-β (TGF)-β, chemokines and growth factors where they are found to 
bind to proteoglycans (Gordon, 2003). While monocytes have a short life span where they undergo 
spontaneous apoptosis every day, macrophages are long-lived cells with a life-span range from 
months to years (van Wilgenburg et al., 2013, Fahy et al., 1999). Monocyte-derived tissue 
macrophages can re-enter the blood stream and differentiate into DCs which depends on different 
stimuli such as phagocytosis and leukotrienes (Randolph, 2001, Gordon, 2003). Under the 
influence of different inflammatory and immune stimuli, local macrophages get activated which 
also enhances recruitment of monocytes from bone-marrow which results in macrophage 
accumulation in the affected tissue (Gordon, 2003). 
Macrophage Receptors 
Macrophages express pattern recognition receptors (PRRs) on their surface including 
TLRs, C-type lectin receptors (CLRs), scavenger receptors (SRs), nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs) and  retinoic acid-inducible gene-I (RIG-
I)-like receptors (RLRs) that help in recognizing danger signals and the presence of foreign 
substances or dead cells (Murray and Wynn, 2011). These receptors initiate inflammatory 
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signaling resulting in macrophage activation (Ivashkiv, 2011). Activated macrophages produce 
different chemokines, cytokines, and inflammatory mediators as a result of activation of different 
signaling pathways such as MAPK, nuclear factor-κB (NF-κB), and interferon regulatory factors 
(IRFs) (Ivashkiv, 2011). Phagocytosis and pathogens binding by macrophages are facilitated by 
different receptors such as mannose receptor (CD206) a type of PRR, or macrophage receptor with 
collagenous structure (MARCO). Other PRR receptors such as TLRs, RLRs, or NLRs are 
expressed on the surface or in the cytoplasm of macrophages and they mediate microbial product 
recognition which induces expression of transcriptional factors and leads to phagocytosis and 
macrophage activation (Murray and Wynn, 2011, Gordon and Taylor, 2005).  Following 
macrophage activation, SRs which are type of PRR facilitate opsonization and removal of 
pathogens, dead cells, cell debris, and foreign molecules from the tissues and the circulation of the 
host (Gordon and Taylor, 2005, Murray and Wynn, 2011). 
Macrophage Polarization 
Macrophage functions and phenotypes can be defined by its polarization state and that 
depends on the type of stimulus (Kittan et al., 2013). Polarized macrophages can be divided into 
classically activated (M1) and alternatively activated (M2) which can be further subdivided into 
M2a, M2b, and M2c (Kittan et al., 2013, Lawrence and Natoli, 2011, Bannon et al., 2013). 
Macrophages can adapt to the type of the stimulus resulting in heterogeneity of macrophages based 
on the function needed in response to the activating signals (Wang et al., 2014, Lawrence and 
Natoli, 2011).  In addition, bone marrow-derived macrophages (BMDMs) that are grown in the 
presence of GM-CSF resulted in differentiation into M1 type which can produce IL-12 while 
grown BMDMs in presence of M-CSF resulted in differentiation into M2 type that produce IL-10 
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(Takeuch and Akira, 2011).  The polarized state of macrophages has been reported to be connected 
to the cytokines produced by TH cells (Bannon et al., 2013). 
The M1 macrophage phenotype has a high expression of MHC class II molecules and co-
stimulatory CD80/86 molecules, whereas the M2 macrophage phenotype have high expression of 
CD206/ or CD163 (Tiemessen et al., 2007, Juhas et al., 2015). Different types of human and mouse 
tissue macrophages express the CD68 surface marker (Nucera et al., 2011). It has been reported 
that CD163 or CD68 in combination with pSTAT1 or RBP-j maybe used as markers for the M1 
phenotype, while a combination of c-MAF with CD163 or CD68 may be used as markers for the 
M2 phenotype (Barros et al., 2013). 
Macrophage Activation 
Classical activation of macrophages through TLR stimulation by ligands such as LPS and 
some cytokines such as IFN-γ resulted in M1 phenotype (Banerjee et al., 2013).  M1 activation 
produces certain pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, IL-12, IL-23, 
chemokines such as CCL5, CCL8, CXCL2, and CXCL4, and upregulate nitric oxide synthase 
(iNOS)  expression that promotes production of nitric oxide (NO) (Sica et al., 2015). In addition, 
different transcription factors involved in M1 macrophage activation include NF-κB, activator 
protein-1 (AP-1), PU.1, CCAAT/enhancer binding protein (C/EBP) α, STAT1, and IRF5 
(Banerjee et al., 2013, Lawrence and Natoli, 2011). Furthermore, M1 macrophages increase in 
abundance during antigen presentation and pathogen removal (Sica et al., 2015, Espinoza-Jiménez 
et al., 2012). 
Alternatively, activation of the M2 phenotype results in upregulation of markers such as 
inter alia arginase-1, FIZZ1 (RELMα), Ym1, mannose receptor, MHC class II, CD14 receptor, 
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CCL17, CCL22, and CCl24 (Locati et al., 2013, Takeuch and Akira, 2011, Gordon, 2003). The 
M2 phenotype plays a role in regulation of the immune response to parasites, allergic reactions, 
tissue remodeling, angiogenesis, and tumor progression (Takeuch and Akira, 2011). Different 
cytokines involved in directing macrophage activation towards the M2 phenotype include IL-4 
and IL-13, as well as IL-33 (Wang et al., 2014, Locati et al., 2013, Kurowska-Stolarska et al., 
2009). IL-4 and IL-13 are well established in their association with TH2-type response and their 
effect on macrophages and other immune cells (Brombacher, 2000, Brubaker and Montaner, 2001, 
Montaner, 1999). Interestingly, IL-10 has similarity to a TH2 cytokine and can be found to be co-
induced with TH2 cytokines during the immune response (Gordon, 2003). IL-10 is a 
multifunctional cytokine that can inhibit antigen-presenting cell function and induce and activate 
different genes (Moore et al., 2001, Gordon, 2003, Lang et al., 2002a, Lang et al., 2002b, 
Montaner, 1999). Recombinant IL-4 has been reported to upregulate expression of MHC class II 
proteins and increase activity of the mannose receptor (McInnes and Rennick, 1988, Stein et al., 
1992). IL-4 also partially inhibits pro-inflammatory cytokines such as TNF as a response to LPS 
compared to IL-10 which is a potent inhibitor to these pro-inflammatory cytokines (Mokoena and 
Gordon, 1985, Gordon, 2003). IL-13 has been reported to exhibit the same effect as IL-4 on mouse 
macrophages, as well as moderately inhibit nitric oxide synthase 2 (NOS2) compared to potent 
inhibition by IL-10 (Doherty et al., 1993, Doyle, 1994). Same effects produced by IL-13 in human 
blood monocyte-derived macrophages (MDMs) but with higher expression of MHC class II and 
mannose receptor levels but not with IL-4 (de Waal Malefyt, 1993, Hart, 1999). In addition, IL-4 
and IL-13 have been reported to increase endocytosis through activation of the mannose receptor 
(Montaner, 1999). Furthermore, IL-4 and IL-13 can induce arginase activity and inhibition of 
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NOS2 activation and NO release which results in increased collagen production which explains 
their involvement in fibrosis and granulomatous inflammation (Gordon, 2003). 
IL-4 and IL-13 share a common receptor chain which produces similar effects on 
macrophages and other immune cells.  However, the presence of different subunits on these 
receptors leads to different cells types responding to them (Gordon, 2003). IL-4 and IL-13 can 
activate signaling pathways including Janus-activated kinase (JAK) and signal transducer and 
activator of transcription (STAT) families (Shimoda, 1996, Takeda et al., 1996). M2 macrophage 
activation has been reported to be promoted by different transcription factors such as IRF4, C/EBP-
β, Krüppel-like factor 4 (KLF4), STAT6, and peroxisome proliferator-activated receptor γ 
(PPARγ) (Lawrence and Natoli, 2011, Banerjee et al., 2013). 
Interaction of Immune System with Nanoparticles 
The immune system acts to protect the host from infections, invading pathogens, and 
unwanted foreign substances.  Following internal or external encounters with invading pathogens 
or foreign substances, the immune system can be suppressed or overstimulated. NPs can be found 
as engineered or naturally-occurring in the environment and are being used extensively in different 
fields such as medicine and industry (Stern and McNeil, 2008). The host can be unintentionally 
exposed to NPs in work places that produce NP-containing products or intentionally exposed as in 
the use of nanomedicines. NPs are used in nanomedicine as delivery vehicles for therapeutic agents 
as well as in imaging studies. NPs can be made of lipids, metals/metal-oxides, silicon and silica, 
polymers, proteins, and carbon (Gentile et al., 2013, Paolino et al., 2014, Shen et al., 2014a, Xu et 
al., 2012, Grigor’eva et al., 2013, Shen et al., 2014b, Molinaro et al., 2013, Choi et al., 2011, Xu 
et al., 2013, Chen et al., 2005, Meng et al., 2013). Once NPs enter the biological system, phagocytic 
cells such as macrophages are the first to interact with NPs which may suppress or overstimulate 
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the immune system which can result in toxic effects.  These effects include granuloma formation 
in lung and skin when animals are exposed to carbon nanotubes (CNTs) (Poland et al., 2008, 
Witzmann and Monteiro-Riviere). NPs are also reported to be accumulated primarily in the spleen 
and liver following intravenous injection (Kumar et al., 2010, Lee et al., 2010). 
Immunosuppression can be a desired effect as it enhances treatment of allergic conditions 
and autoimmune diseases or it may be an unwanted effect where it may lower the host’s defense 
against infections and cancer (Ryan et al., 2007, Balenga et al., 2006, Gomez et al., 2007, 
Wegmann et al., 2008, Basarkar and Singh, 2009, Kim et al., 2002, Choi et al., 2008, Sakai et al., 
2006). It has been reported that CNTs can suppress B cell function through transforming growth 
factor produced by macrophages (Mitchell et al., 2009). Another study in breast cancer patients 
reported that paclitaxel bound to human serum albumin NPs showed fewer neutropenia incidents 
compared to the regular paclitaxel formulation  (Stinchcombe et al., 2007, Higaki et al., 2005). In 
addition, in animal model studies, clodronate loaded in liposomes was used to deplete 
macrophages in order to protect animals’ lungs from endotoxin effects (Gaca et al.). 
Immunostimulation by NPs can include activating either the innate or the adaptive immune 
response. Activation of the complement system by NPs can lead to hypersensitivity reactions and 
anaphylaxis (Chanan-Khan et al., 2003, Szebeni, 2005, Szebeni et al., 2007, Szebeni et al., 2002). 
It has been reported that complement activation in tumor tissues induces tumor-associated immune 
cell activation resulted in stimulating cancer progression which may impact the use of 
nanoparticles in cancer diagnosis or treatment (Markiewski et al., 2008, Markiewski and Lambris). 
NPs have also been shown to enhance antigenicity of weak antigens or can act as antigens by 
themselves (Manolova et al., 2008, Reddy et al., 2007, Fifis et al., 2004). NPs can modulate the 
type of immune response by induction of release of different mediators and cytokines such as IFN-
22 
 
γ or IL-4 (Mottram et al., 2007). NPs have been reported to induce production of particle-specific 
antibodies such as fullerene (C60) derivatives and polyamidoamine dendrimers (Braden et al., 
2000, Chen et al., 1998, Lee et al., 2004). 
Allergic reactions are common side effects of NPs which have been reported in different 
studies such as CNTs which can enhance allergic reactions induced by the allergen, ovalbumin 
(OVA), in mice (Nygaard et al., 2009). Occupational exposure of humans to dendrimers has been 
reported to play a role in development of allergic reactions such as epidermal necrolysis-like 
dermatitis in workers exposed to NPs in work places involved in handling of NPs (Toyama et al., 
2008). 
Cytokines produced by immune cells can be released in response to exposure to different 
type of NPs such as gold, colloids, dendrimers, polymers, and lipid NPs (Fifis et al., 2004, Mottram 
et al., 2007, Scholer et al., 2002, Scholer et al., 2001, Shvedova et al., 2005, Vallhov et al., 2006). 
Interaction of Mast Cell with NPs 
Due to the location of mast cells in tissues such as the skin and lungs, mast cells are exposed 
to the external environment which results in this critical cell type acting as sentinel cells in the host 
defense (Brown et al., 2008b). The rapid response of mast cells to the external stimuli results in 
mast cell activation and degranulation and release of pre-formed mediators or newly synthesized 
de novo mediators (Brown et al., 2008b). Mast cells are a main immune cell type that can interact 
with NPs because of their location in the host body and because of its role in the immune system 
response. Thus, understanding the mast cell-NP interaction is important for improved 
understanding of NP toxicity. Mast cells have been reported to be activated by different types of 
NPs such as TiO2 NPs that can increase histamine release and activate mast cells via activation of 
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membrane L-type Ca2+ channels, can also increase ROS production and activate the PLC pathway 
which results in exacerbated allergic inflammatory responses with or without IgE sensitization. 
Based on the previous results, NP exposure may worsen inflammatory diseases associated with 
mast cells such as arthritis (Chen et al., 2012a). Mast cells can also be activated by cerium oxide 
(CeO2) NPs and they have been reported to contribute to pulmonary inflammation, exacerbation 
of myocardial ischemia/reperfusion injury, and release of mediators such as IL-6, MIP-1α, TGF-
β, and osteopontin (Wingard et al., 2011). In that same study, mast cell deficient mice did not show 
any inflammatory response (Wingard et al., 2011). 
Mast cells are involved in allergic responses through activation of FcεRI receptor following 
binding with IgE resulting in the release of many mediators. Mast cells exposed to fullerene C(70)-
tetraglycolic acid have been reported to inhibit degranulation and cytokine production, while 
C(70)-tetrainositol blocked only cytokine production in mast cells which suggested a new 
approach for treatment allergic diseases (Norton et al., 2010, Dellinger et al., 2010, Ryan et al., 
2007). The previous findings showed that NPs can interfere with FcεRI signaling pathways and 
stabilize mast cells by blocking calcium release and ROS generation through initiation of signaling 
pathways  such as extracellular signal regulated kinase 1/2 (ERK),  p38-MAPK, linker of activated 
T cells (LAT), phosphoinositide 3-kinase (PI3K), and v-src (Norton et al., 2010). Multi-walled 
carbon nanotubes (MWCNTs) can activate mast cells and it has been reported that mast cell 
exposure to MWCNTs leads to production of IL-33 that activates mast cells and results in adverse 
pulmonary and cardiovascular responses in normal mice which were confirmed by testing mast 




The mechanisms of mast cell activation by NPs exposure are not well understood 
necessitating the need for further investigation of NP-mast cell induced toxicity and the underlying 
mechanisms. This may allow for design of better formulations of NPs with less side effects that 
can effectively be used in medicine and consumer products. 
Interaction of Macrophages with NPs 
Macrophages are important immune cells in host defense due to their phagocytic function 
which acts to engulf and remove pathogens and foreign substances from the body. Phagocytosis 
of NPs has been reported in different studies and can occur within a range of time from minutes to 
hours (Tsai et al., 2012, Geiser et al., 2008, Takenaka et al., 2006, Semmler-Behnke et al., 2007). 
NPs are likely to be taken up by different mechanisms such as micropinocytosis and pinocytosis 
(Geiser, 2010). In micropinocytosis, large vesicles ranging in size from 0.2-10 μm are formed 
spontaneously or following stimulation by growth factors resulting in particle internalization by 
macrophages and other cells (Geiser, 2010). Pinocytosis forms vesicles 100nm in diameter and 
can be divided in two types including clathrin-mediated pinocytosis and caveolae mediated 
pinocytosis (Geiser, 2010). Uptake and internalization of NPs with sizes up to 200nm in diameter 
have been reported to use clathrin-mediated pathways, whereas caveolae-mediated pathway is 
utilized for larger size NPs with diameter up to 500nm (Rejman et al., 2004). Upon NP 
internalization, the NPs can translocate to different locations and interact with different types of 
macrophages or other types of cells as it has been reported that NPs can pass the epithelial barrier 
into the interstitium and enter the blood circulation following inhalation exposure (Semmler-
Behnke et al., 2007). 
Macrophages can be activated following NP exposure resulting in production of different 
mediators such as pro-inflammatory cytokines, ROS, and nitric oxide. It has been reported that 
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MWCNTs can induce cyclooxygenase-2 (COX-2) through ERK 1/2 pathway activation and iNOS 
stimulation which was found to be ERK 1/2 independent (Lee et al., 2012). Interaction of silica 
NPs with macrophages has been reported to induce cytotoxicity and oxidative stress in murine 
alveolar macrophages (Gazzano et al., 2012). 
NP size has been reported to play an important role in macrophage activation as different 
studies showed that NPs such as AgNPs and gold NPs can induce cytotoxicity and ROS generation 
in a size-dependent manner (Tsai et al., 2012, Carlson et al., 2008). 
Different studies showed the important role of alveolar macrophages in NP removal which 
correlates to the role of macrophages in pulmonary responses following NP exposure such as 
AgNPs and gold NPs (Takenaka et al., 2012, Haase et al., 2011). In the previous studies, AgNPs 
were reported to be internalized by macrophages within minutes while gold NPs were taken up by 
macrophages within 24 hours. In addition, alveolar macrophages have been reported to interact 
with and take up single-walled carbon nanotubes (SWCNTs) in a manner that was dependent on 
the type of NP coating and the surfactant used in the study (Kapralov et al., 2012, Ruge et al., 
2011). Furthermore, macrophages in the pleural space have been reported to interact with CNTs 
which resulted in increased production of cytokines such as IL-1β, TNFα, IL-6 and the chemokine, 
IL-8 which can lead to mesothelioma induction (Murphy et al., 2012). 
Scavenger Receptors 
SRs were first described in 1979 by Drs. Michael Brown and Joseph Goldstein in their 
work investigating the uptake and internalization of low-density lipoprotein (LDL) by cells 
(Brown and Goldstein, 1979, Brown et al., 1979). Now SRs are recognized to have a wide range 
of ligands in addition to LDL such as endogenous proteins and lipoproteins, as well as, microbial 
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associated products such as LPS and lipoteichoic acid (LTA) (Pluddemann et al., 2011, 
Plüddemann et al., 2006). The mammalian SRs can be distributed into classes designated A to J, 
however the class C scavenger receptor is not included because it is only expressed in Drosophila 
melanogaster (Canton et al., 2013, PrabhuDas et al., 2014b).  In a recent published report, it was 
proposed that a method for SR nomenclature be developed to provide clarity (PrabhuDas et al., 
2014a). As an example, a member for SR class A would be designated as SR-A1, where SR stands 
for scavenger receptor followed by a hyphen, then a capital letter such as A to represent the class 
of SR followed by Arabic numeral to represent the type of molecule within the class. If there are 
alternate splice variants, then it would be designated by a dot and an Arabic numeral such as SR-
A1.1 (PrabhuDas et al., 2014b). The previous report explained in detail the nomenclature for SR 
family members.  In summary, class A of SR includes SR-A1 (also known as macrophage 
scavenger receptor 1 (MSR1), CD204, or SCARA1, SR-A1.1 (also known as SR-AII), SR-A1.2 
(also known as SR-AIII), SR-A3 (also known as MSRL1, APC7, or SCARA3), SR-A4 (also 
known as COLEC12, SR C-type lectin (SRCL), SCARA4, or CL-P1), SR-A5 (also known as 
TESR, NET33, or SCARA5), SR-A6 (also known as  MARCO, Ly112, or SCARA2). Class B of 
SR includes SR-B1 (also known as SR-BI, SCARB1, or CD36L1), SR-B1.1 (also known as SR-
BII), SR-B2 (also known as CD36, SCARB3, FAT, GPIV, or PAS4), and SR-B3 (also known as 
SCARB2, lysosomal integral membrane protein 2 (LIMP2), CD36L2, or LGP85). Class D of SR 
includes SR-D1 (also known as CD68, gp110, SCARD1, Macrosialin, or lysosomal associated 
membrane protein 4 (LAMP4). Class E of SR includes SR-E1 (also known as lectin-like oxidized 
low-density lipoprotein receptor-1(LOX-1), SCARE1, CLEC8A, or OLR1), SR-E1.1 (also known 
as LOXIN), and SR-E2 (also known as Dectin-1 or CLEC7A). Class F of SR includes SR-F1 (also 
known as scavenger receptor expressed by endothelial cells I (SREC-I) or SCARF1), SR-F2 (also 
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known as SREC-II or SCARF2), and SR-F3 (also known as multiple EGF-like domains 10 
(MEGF10), GM331, or EMARDD). Class G of SR includes only SR-G1 (also known as scavenger 
receptor for phosphatidylserine and oxidized low-density lipoprotein (SR-PSOX) or CXCL16). 
Class H of SR includes SR-H1 (also known as fasciclin, EGF-like, laminin-type EGF-like, and 
link domain-containing scavenger receptor-1 (FEEL-1) or STAB1) and SR-H2 (also known as 
FEEL-2 or STAB2). Class I of scavenger receptor includes SR-I1 (also known as CD163 or 
M130), SR-I1.1, SR-I1.2, and SR-I2 (also known as CD163B, CD163L1, or M160). Class J of SR 
includes SR-J1 (also known as receptor for advanced glycation end products (RAGE)) and SR-
J1.1 (PrabhuDas et al., 2014b). Other molecules that have scavenging activity but are still not 
classified within the SR family include the LDL receptor family proteins such as LRP1, 
LRP2/megalin, and CD11b/CD18α (PrabhuDas et al., 2014b). 
In addition to their scavenging activity, SRs act as lipid transporters and even act as 
chemokines (Shimaoka et al., 2004b, Gu et al., 1998, Kennedy and Kashyap, 2011). CD36 has 
been reported to be involved in atherosclerosis by inducing the formation of foam cells and also 
has been proposed to be involved in granulomatous conditions such as tuberculosis by its role in 
formation of multinucleated giant cells to prevent spreading of the pathogens (Helming et al., 2009, 
Martin et al., 2011a, Martin et al., 2011b). LIMP2, a member of SR class B, has been reported to 
be involved in transportation of β-glucocerebrosidase from the endoplasmic reticulum (ER) to the 
lysosomes. Therefore impairment in LIMP2 function can be correlated to neurodegenerative and 
renal disorders (Reczek et al., 2007, Blanz et al., 2010, Desmond et al., 2011). Feel-1 a member 
of SR class H has been reported to affect lysosomal delivery of chitinase-like protein which in turn 
affects macrophage mediated uptake and degradation of unwanted self-molecules and which can 
affect production of mediators by macrophages (Kzhyshkowska et al., 2006). Previous reports 
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suggested that SRs have important roles in the cellular functions including those within the cell, 
and on the cell surface as well as in the circulation. 
The recognition of SRs to self-molecules such as endogenous proteins and non-self-
molecules (PAMPs) led them to be classified as pattern recognition receptors (PRRs) (Krieger, 
1997, Medzhitov and Janeway, 2002). The SR family shares some functional properties such as 
identifying and removing self-molecules including dead cells and damaged proteins or non-self-
molecules including microorganisms and foreign substances, whereas their structures are very 
heterogeneous between classes and even among members of each class (Plüddemann et al., 2006, 
Mukhopadhyay and Gordon, 2004, Pluddemann et al., 2007, Suzuki et al., 1997, Taylor et al., 
2005, Herrmann et al., 2012). Molecule removal induced by SRs can be carried out by simple 
endocytosis or can be produced through processes requiring signal transduction such as 
phagocytosis or micropinocytosis (Canton et al., 2013). The SR families can also be involved in 
other processes such as cellular adhesion and antigen presentation (Palani et al., 2011, Shimaoka 
et al., 2004a, Santiago-Garcia et al., 2003).  Due to their various functions, SRs have been found 
to be involved in the maintenance of homeostasis and in the pathogenesis of different diseases 
(Canton et al., 2013).  In addition, metabolism and inflammatory disorders have been linked to 
SRs for their involvement in innate immunity and their affinity for modified lipids, pathogens, and 
foreign molecules (Feng et al., 2011, Kzhyshkowska, 2010, Park et al., 2013, Podrez et al., 2007, 
Silverstein and Febbraio, 2009). 
Scavenger Receptor B1 
Scavenger Receptor B1 (SR-B1) is a cell surface glycoprotein with a large middle part of 
its structure located extracellularly and attached to the plasma membrane by transmembrane 
domains with short N- and C-terminal cytoplasmic domains (Figure 1.1) (Acton et al., 1994, Calvo 
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and Vega, 1993). SR-B1.1 is an alternatively spliced variant of SR-B1 mRNA that lacks the C-
terminal cytoplasmic domain (Webb et al., 1997). SR-B1 is distributed in different cells and tissues 
including hepatocytes, platelets, macrophages, mast cells, endothelial cells, and epithelial cells 
(Brown et al., 2009, Dieudonne et al., 2012, Uittenbogaard et al., 2000, Kzhyshkowska et al., 
2012).  SR-B1 can bind to various ligands such as high-density lipoprotein (HDL) cholesterol, 
oxidized and acetylated LDL (OxLDL and AcLDL), very low density lipoprotein (VLDL), and 
phospholipids (Krieger, 2001). SR-B1 activity has been reported to be controlled by PDZK1 which 
is a PDZ containing protein primarily expressed in kidney, liver, and small intestine and can 
interact with the C-terminal resulting in signaling pathway activation such as Akt and MAPKs 
(Ikemoto et al., 2000, Kocher et al., 1998, Nourry et al., 2003, Mineo et al., 2003). The main 
function of SR-B1 is to mediate cellular HDL uptake as well as to mediate bidirectional flux of 
unesterified cholesterol and phospholipids between HDL and cells (Krieger, 2001). Therefore, SR-
B1 can play important role in cholesterol metabolism which has been addressed by using a SR-B1 
knock out mice model that was characterized by an increase in plasma total cholesterol, decreased 
cholesteryl ester stores, and reduced biliary cholesterol secretion (Rigotti et al., 1997b, Trigatti et 
al., 1999, Mardones et al., 2001, Huszar et al., 2000, Temel et al., 1997). 
Role of Scavenger Receptors in Macrophage Polarization 
SRs contribute in macrophage polarization and some SRs are found to be highly expressed 
in the M2 phenotype such as SR-A1 and CD36 as well as CD163 where its expression can be used 
as M2 phenotype marker (Van Gorp et al., 2010, Oh et al., 2012, Buechler et al., 2000, Weaver et 
al., 2007, Xu et al., 2007, Tippett et al., 2011). SR-A1 and CD36 can contribute to M2 generation 
by delivering signals to ER stress pathways, Jun N-terminal kinase (JNK), PPARγ pathways that 
are required for M2 generation (Oh et al., 2012). Increased expression of SR-A1 and CD36 has 
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been reported to enhance M2 function in removing molecules such as apoptotic cells (Todt et al., 
2008, Ogden et al., 2005, Xu et al., 2006, Zizzo et al., 2012). CD36 is highly expressed in M2 
macrophages and has an anti-inflammatory function but can also be found in M1 macrophages 
where it can induce production of pro-inflammatory cytokines following an interaction with TLRs 
(Triantafilou et al., 2006, Hoebe et al., 2005, Kennedy et al., 2011).  On the other hand, CD163 
can promote anti-inflammatory effects in M2 macrophages by inactivating pro-inflammatory 
molecules such as TNF-like weak inducer of apoptosis (Bover et al., 2007, Schaer et al., 2007, 
Philippidis et al., 2004). Therefore, SRs are highly expressed in M2 macrophages but they can also 
be expressed on other macrophage cell populations and can induce pro-inflammatory cytokine 
production by macrophages. 
Scavenger Receptors and Immune System 
SRs can recognize PAMP molecules in addition to scavenging modified lipoproteins. SRs 
have an important role in innate immunity through their action in phagocytosis and removal of 
pathogens (Mukhopadhyay and Gordon, 2004, Pluddemann et al., 2011). 
Different ligands can bind to a single SR resulting in wide range of substances that are 
covered by SRs. SR-A1 and MARCO have been reported to bind to bacterial-associated molecules 
such as LPS, LTA, and CpG DNA resulting in uptake of the source pathogen (Suzuki et al., 1997, 
Mukhopadhyay and Gordon, 2004, Peiser et al., 2006, Thomas et al., 2000, Peiser et al., 2002). 
Furthermore, some ligands overlap among different SRs such as SR-A1 and MARCO that can 




SRs can influence other PRRs such as TLRs and have an impact on their signaling. SR-A1 
can influence TLR4 and induce phagocytosis of Gram-negative bacteria such as Escherichia coli, 
while interaction of SR-A1 with TLR2 can induce phagocytosis of Gram-positive bacteria such as 
Staphylococcus aureus (Amiel et al., 2009). Furthermore, the interaction of SR-A1 and TLR3 has 
been reported to enhance pathogen uptake and the inflammatory response (Mukhopadhyay et al., 
2011). MARCO can also interact with TLRs as it has been reported that interaction of MARCO 
with TLR2 and CD14 in the process of recognition to Mycobacterium tuberculosis cell wall 
glycolipid results in pro-inflammatory cytokine production (Bowdish et al., 2009). 
CD36 which is a member of class B SR family can interact with TLRs such as TLR2 and 
TLR6 in response to bacterial-associated molecules such as LTA resulting in cytokine production 
and infected cell internalization (Stewart et al., 2010, Triantafilou et al., 2006). CD36 also has been 
reported to be required for induction of mycobacterial infection and CD36 deficiency results in 
attenuated susceptibility to mycobacterial infection (Philips et al., 2005). SR-B1 has been reported 
to act as co-receptor for hepatitis C virus internalization inside the cell (Ploss et al., 2009, Dreux 
et al., 2009, Westhaus et al., 2013, Dao Thi et al., 2012). In addition, SR-B1 has been reported to 
play a role in pathogen survival such as Chlamydia trachomatis where this pathogen uses SR-B1 
to provide lipids like phosphatidylcholine that are essential to its survival and inhibition of SR-B1 
resulted in impaired pathogen replication (Cox et al., 2012). Also, SR-B1 has been reported to play 
important role in host defense during bacterial pneumonia where the investigators found that SR-
B1-/- mice showed increased mortality, increased neutrophils recruitment, and cytokine production  
which were associated alteration in LPS clearance by cells (Gowdy et al., 2015). LIMP2 is another 
member of SR class B that has been reported to facilitate cell entry of different type of viruses 
such as enterovirus 71 and coxasckievirus (CVA) such as CVA7, CVA14, and CVA16 as well as 
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play an important role as an infection efficiency determinant which depends on viral uncoating by 
LIMP2 (Yamayoshi et al., 2009, Yamayoshi et al., 2012, Yamayoshi et al., 2013). 
Interaction of Scavenger Receptors with Nanoparticles 
Interaction of SRs with NPs has been reported in various studies. SR-A receptors such as 
SR-A1 have been reported to mediate amorphous silica NP uptake by macrophages (Orr et al., 
2011). In addition, overexpression of SR-A1 in non-phagocytic cells resulted in cellular uptake of 
amorphous silica NPs and silencing expression of SR resulted in a reduction in amorphous silica 
NP uptake and pro-inflammatory cytokine production (Orr et al., 2011). SR-A1 also has been 
reported to contribute to cellular uptake of superparamagnetic iron oxide NPs following bacterial 
exposure which resulted in IL-10 inhibition, an increase in TNF-α production, modulation of TLR4 
gene expression, and dysregulation of macrophage activation profiles which affect macrophage 
polarization from the M1 into the M2 phenotype (Kodali et al., 2013). Furthermore, 
superparamagnetic iron oxide NPs were found to impair antimicrobial function by macrophages 
in response to LPS exposure (Kodali et al., 2013). MARCO another member of SR class A has 
been reported to play a role in the interaction with NPs such as MWCNTs, superparamagnetic iron 
oxide NPS, and polystyrene nanoparticles (Chao et al., 2012, Hirano et al., 2008). In addition, 
MARCO was found to contribute to AgNP uptake where macrophages isolated from MARCO-/- 
mice showed less NP uptake and less toxic effects compared to macrophages isolated from wild 
type mice (Hamilton et al., 2014). 
Fewer studies described the interaction of NPs and SRs class B. SR-B1 was found to 
contribute in synthetic layered silicate NP recognition and clearance by phagocytosis (Mortimer 
et al., 2014). Another study reported that chitosan NP as a non-viral delivery carrier of siRNA in 
HePG2 cell line resulted in SR-B1 silencing for up to 96 hours which demonstrated and interaction 
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between SR-B1 and NPs  (Farid et al., 2014, Lin et al., 2012). Synthetic high density lipoprotein 
NPs also have been reported to interact with SR-B1 which have been suggested for use in treatment 
of B-cell lymphoma by inducing apoptosis (Yang et al., 2013). In addition, SR-B1 has been 
reported to facilitate paclitaxel encapsulated in HDL-NPs uptake by cancer cells which can be used 
to increase treatment efficiency (Mooberry et al., 2010).  
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Goal of Research and Statement of Hypothesis 
AgNPs have been reported to induce toxicity such as oxidative stress and DNA damage. 
The influence of physicochemical properties of AgNPs on mast cell and macrophage activation 
has not been investigated. In addition, the mechanism by which the AgNPs bind to and interact 
with cells is still unclear. 
The goal of this research was to evaluate mast cell and macrophage activation following 
AgNP exposure. Mast cells and macrophages have shown the ability to interact with different types 
of NPs and induce toxic effects, therefore it is important to understand the effect of the 
physicochemical properties of AgNPs and the nature and role of receptors involved in toxicity 
induction. Therefore, this project will provide information that has an impact on formulating 
nanomedicine products and consumer products exhibit low toxic profiles. 
Specific Aims 
This project is based on the main hypothesis which states that the scavenger receptor B1 
(SR-B1) mediates mast cell and macrophage uptake of silver nanoparticles (AgNPs) and 
subsequent inflammatory responses. To test this hypothesis, three aims were developed as follows: 
Aim 1: Investigate Silver Nanoparticle (AgNP) uptake by mast cells and macrophages. 
This aim will evaluate uptake of AgNPs by bone marrow derived mast cells (BMMCs) and 
murine macrophages (RAW 264.7) cell line. Different methods will be used in this aim including 
enhanced darkfield hyperspectral imaging technology (Cytoviva) to image AgNPs in cells and to 
create hyperspectral profiles for mapping AgNPs within cells, flow cytometry, and inductively 
coupled plasma mass spectrometry (ICP-MS). 
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Aim 2: Investigate mast cell and macrophage activation following AgNP exposure. 
This aim will quantitatively evaluate cell activation following AgNP exposure.  BMMC 
cytokine release and degranulation will be measured following AgNP exposure. In addition, PCR 
array, activation markers, and cytokine release will be evaluated in macrophages. 
Aim 3: Establish a role of the scavenger receptor B1 (SR-B1) in mast cell and macrophage uptake 
and activation following AgNPs exposure. 
This aim will focus on the role of SR-B1 in AgNP uptake and cellular activation by using 
an SR-B1 inhibitor 2-(2-butoxyethyl)-1-cyclopentanone thosemicarbazone (Blt2) in in vitro 
studies or by using Blt2 in an in vivo study in addition to SR-B1-/- mice.  
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Figure 1.1 Proposed pathway of silver nanoparticles binding to scavenger receptor B1 and 
subsequent inflammatory responses 
Silver nanoparticles (AgNPs) interact with scavenger receptor (SR-B1) which is a protein with 2 
transmembrane domains and intracellular N and C termini. PDZK1 is a PDZ containing protein 
can interact with the C-terminal resulted in signal pathways activation following AgNPs exposure. 
By using blocking lipid transporter-2 (Blt2) which is an SR-B1 inhibitor, the signal pathway 







CHAPTER 2: INFLUENCE OF PHYSICOCHEMICAL PROPERTIES OF SILVER 
NANOPARTICLES ON MAST CELL ACTIVATION AND DEGRANULATION 
 




Silver nanoparticles (AgNPs) are increasingly being incorporated into products for their 
antimicrobial properties. This has resulted in increased human exposures and the possibility of 
adverse health effects. Mast cells orchestrate allergic immune responses through degranulation and 
release of pre-formed mediators. Little data exists on understanding interactions of AgNPs with 
mast cells and the properties that influence activation and degranulation. Using bone marrow-
derived mast cells and AgNPs of varying physicochemical properties we tested the hypothesis that 
AgNP physicochemical properties influence mast cell degranulation and osteopontin production. 
AgNPs evaluated included spherical 20 nm and 110 nm suspended in either polyvinylpyrrolidone 
(PVP) or citrate, Ag plates suspended in PVP of diameters between 40-60 nm or 100-130 nm, and 
Ag nanowires suspended in PVP with thicknesses ˂100 nm and length up to 2 microns. Mast cell 
responses were found to be dependent on the physicochemical properties of the AgNP.  Further, 
we determined a role for scavenger receptor B1 in AgNP-induced mast cell responses.  Mast cell 
degranulation was not dependent on AgNP dissolution but was prevention by tyrosine kinsase 
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inhibitor pretreatment. This study suggests that exposure to AgNPs may elicit adverse mast cell 




The applications of nanotechnology are rapidly expanding and revolutionizing many fields 
primarily through the incorporation of nanoparticles (NPs) into numerous biomedical and 
consumer products. In particular, silver nanoparticles (AgNPs) are one of the most utilized NPs 
due to their antimicrobial/fungal properties (Nocchetti et al., 2013, Dong et al., 2012, Levard et 
al., 2013). More than 300 globally available consumer products, such as wound dressings, IV bags, 
dermal creams, water filters, and many household products, incorporate AgNPs (Project, 2014). 
Indeed, the annual global production of AgNPs is estimated to be >55 tons (Piccinno et al., 2012). 
A direct interaction of end user and AgNP-based products increases the risk of possible exposure 
through Ag or Ag+ leaching out from these products and could possibly result in adverse health 
outcomes (Christensen et al., 2010). For instance, AgNPs used as coatings on surgical implants 
may enter into the systemic circulation and translocate into different organs such as the lung and/or 
liver (Rahman et al., 2009, Tang et al., 2009). More importantly, some food storage containers that 
use AgNP coatings that have been found to release nanostructured Ag into food due to an increase 
dissolution under high salt concentration (Echegoyen and Nerín, 2013). Animal studies have 
demonstrated that AgNP exposure results in hepatotoxicity and pulmonary inflammation (Sung et 
al., 2008, Tiwari et al., 2011). In addition, AgNPs have been reported to interact with immune cells 
and induce cytotoxicity through the generation of reactive oxygen species (Carlson et al., 2008, 
Nishanth et al., 2011).  To date, limited research exists evaluating the ability of NPs to directly 
interact with immune cells involved in allergy such as mast cells and possibly resulting in or 
exacerbation of allergic disease. 
Mast cells are found in most tissue types and play an important role in innate immunity, 
host defense and allergic disease (Brown et al., 2008a). Mast cells are well studied for their role in 
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allergic disease and activation through IgE and the high affinity IgE receptor (FcRI) leading to 
the release of a variety of mediators including histamine, serotonin, and inflammatory cytokines 
such as TNF-α, osteopontin (OPN), and eosinophil chemoattractant factor as examples (Brown et 
al., 2008a).  In addition, mast cells recognize pathogens through toll-like receptors and scavenger 
receptors (McCurdy et al., 2003, Medic et al., 2008). Recent animal studies have demonstrated 
that mast cells contribute to the inflammatory response following NP exposures.  Specifically, it 
has been reported that mast cells are involved in lung inflammation and fibrosis following 
exposure to multi-walled carbon nanotubes (Katwa et al., 2012). In addition, mast cells have been 
shown to be involved in cerium oxide-induced alterations in vascular reactivity (Wingard et al., 
2011).  Even though mast cells appear to be central in the pathogenesis following NP exposure 
little research has been done assessing the direct interaction of NPs with mast cells.  While mast 
cells are well-known to be involved in allergic conditions, it is currently unclear if NPs have the 
capacity to induce and/or promote an allergic disease state (Shannahan and Brown, 2014, 
Shannahan et al., 2012, Podila and Brown, 2013). One study reported that AgNPs can induce mast 
degranulation in mast the RBL-2H3 rat basophilic cell line, however, the study was focused on 
real-time live cell imaging of the degranulation process but not the influence of physicochemical 
properties of AgNPs (Yang et al., 2010b). In another study, researchers used mouse peritoneal 
mast cells to compare uptake of spherical Au and Ag NPs (Marquis et al., 2011). This study 
demonstrated that positively charged NPs were internalized more than negatively charged NPs 
while mast cell degranulation was decreased in cells exposed to negatively charged AgNPs.   While 
mast cells are well-known to be involved in allergic conditions, it is currently unclear if NPs have 
the capacity to induce and/or promote an allergic disease state (Podila and Brown, 2013, 
Shannahan and Brown, 2014, Shannahan et al., 2012). 
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Scavenger receptors are well known for their role in recognizing and binding lipid 
molecules such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL) (Goldstein 
et al., 1979, Krieger and Herz, 1994, Landschulz et al., 1996). Scavenger receptor B1 (SR-B1) is 
a multi-ligand receptor that preferentially binds lipid molecules and other negatively charged 
molecules (Krieger and Herz, 1994, Landschulz et al., 1996, Rigotti et al., 1997a). Furthermore, 
SR-B1 has been reported to recognize and bind with pathogens and NPs (Eyre et al., 2010, 
Mooberry et al., 2010). Many different types of cells express SR-B1 including epithelial cells, 
endothelial cells, and macrophages.  Specifically, the cellular uptake of AgNPs by macrophages 
and subsequent apoptosis has been shown to be scavenger receptor dependent (Singh and 
Ramarao, 2012).  Therefore it is likely that other cells, which express scavenger receptors on their 
surface such as mast cells, may interact with AgNPs similarly and this receptor interaction may 
mediate toxic responses. 
In this study, we hypothesized that NP physicochemical properties such as size, shape, and 
surface coating will influence mast cell degranulation through interaction with SR-B1. To address 
this hypothesis, bone marrow derived mast cells were used to assess AgNP directed degranulation 
using AgNPs of differing size, shape and surface coating. Lastly, we evaluated the role of SR-B1 





Materials and Methods 
Silver Nanoparticles   
20 and 110 nm spherical AgNPs either suspended in citrate (C20 and C110) or 
polyvinylpyrrolidone (PVP) (P20 and P110) were procured through the National Centers for 
Nanotechnology Health Implications (NCNHIR) and initially characterized by the National 
Characterization Laboratory at the National Cancer Institute. Two types of nanoplates with optical 
resonance peak at specific wavelengths of 550 nm and 850 nm suspended in PVP (P550 and P850), 
or Ag nanowires that are up to 2 µm suspended in PVP were purchased from NanoComposix at a 
concentration of 1 mg/ml. All AgNPs were negative for endotoxin contamination. 
Silver Nanoparticle Characterization   
The hydrodynamic size and Zeta potentials (ZetaSizer Nano, Malvern) of all AgNPs were 
characterized in N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES). All 
measurements were performed with 3 individuals samples at a concentration of 50 μg/ml.   The 
size and shape of the AgNPs were confirmed via transmission electron microscopy (TEM, Hitach 
H7600). Size distribution analysis was performed using the freeware software Image J. A 
minimum of 100 particles per sample were counted by randomly surveying the entire TEM grid 
from multiple high magnification images. Image J was used to determine both area and Feret 
diameters (the greatest distance between two points on an objects boundary). 
Reagents and Antibodies   
SR-B1 inhibitor 2-(2-butoxyethyl)-1-cyclopentanone thosemicarbazone (Blt2) 
(Chembridge Corp., San Diego, CA, USA), Rat Lysosome-associated membrane proteins 2 
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(Lamp2) anti-mouse antibody (eBioscience Inc., San Diego, CA, USA), Imatinib (Cayman 
Chemical Company, Ann Arbor, MI, USA) 
Cell Culture  
Bone marrow-derived mast cells were cultured from femoral marrow cells of C57Bl/6 mice 
(Jackson Laboratories, Bar Harbor, ME). Bone marrow from 2 mice were used for each batch of 
mast cells. Cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 100 μg/ml PrimocinTM (Invivogen, San Diego, CA), 25 mM 
HEPES, 1.0 mM sodium pyruvate, nonessential amino acids (BioSource International, Camarillo, 
CA), 0.0035% 2-ME and 300 ng/ml recombinant mouse IL-3 (PeproTech, Rocky Hill, NJ). Mast 
cells were used following 4-6 weeks of culture at 37°C and 5% CO2. All animal procedures were 
conducted in accordance with the National Institutes of Health guidelines and approved by the 
University of Colorado Denver Institutional Animal Care and Use Committee. All animals were 
treated humanely and with regard for alleviation of suffering. Cytotoxicity of AgNPs at 
concentrations used in this study were evaluated by MTS and LDH assays (Promega, Madison 
WI) and did not induce cytotoxicity effect compared to the control group (data not shown). Further 
these concentrations were based on the evaluation of other nanoparticles which have utilized 
similar concentrations as performed by the NIEHS Nano GO Consortium (Xia et al., 2013) 
Enhanced Darkfield Imaging  
3x105 cells were exposed to AgNPs at concentration of 50 µg/ml for 1 h then washed and 
spun on a glass slide using a Cytospin IV (Shandon Scientific Ltd., Cheshire, UK) at 300 rpm for 
5 min. Cells were then fixed in 2% paraformaldehyde solution for 10 min at 37oC then washed 
with phosphate-buffered saline (PBS) three times and mounted with DAPI staining ProLong® 
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(Life Technologies, Carlsbad, CA). Cells were then qualitatively assessed by enhanced darkfield 
microscopy (Cytoviva, Auburn, AL) for uptake of AgNPs by focusing on the DAPI stained 
nucleus. 
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)   
3x105 cells were pretreated with or without the scavenger receptor B1 (SR-B1) inhibitor 
Blt2 at a concentration of 50 µM. After 30 min, cells were exposed to AgNPs at concentration of 
50 µg/ml for 1 h.  Following exposure, samples were collected and centrifuged for 10 min at 14,000 
rpm (20,817 g) and washed three times with PBS to remove excess AgNPs. All samples were 
dissolved in 6 ml of 2% HNO3.  Subsequently, the Ag cellular concentration was determined with 
ICP-MS (X series II, Thermo Scientific) using an internal standard containing Li, Y, and In with 
a resolution of 0.1 ppb. All experiments were performed in triplicate from 3 individual batches of 
mature mast cells. Each batch of mast cells was grown from femoral bone marrow of 2 mice. 
Mast Cell Degranulation  
Bone marrow-derived mast cells were seeded at 5 × 104 cells/well in 96-well flat-bottom 
plates for assessment of degranulation by -hexosaminidase release (Iwaki et al., 2005).  For 
treated samples, all types of AgNPs were added at 0, 6.25, 12.5, 25, or 50 μg/ml for 1 h. In addition, 
24 h prior to degranulation measurements a subset of cells were sensitized with 100 ng/ml mouse 
IgE anti-DNP (Sigma-Aldrich, St. Louis, MO) followed by addition of 100 ng/ml 
dinitrophenylated human serum albumin (DNP-HSA) (Sigma-Aldrich) for 1 h to generate a 
positive control. For experiments with Blt2, cells were pretreated with Blt2 at 50 μM for 30 
minutes before being exposed to AgNPs. To assess the contribution of ionic Ag to -
hexosaminidase release, AgNPs were placed into HEPES for 1 h, spun at 3000 g for 10 min into 
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Amicon Ultra-15 Centrifugal Filter Units (EMD Millipore). Filtrate containing ionic Ag was used 
to treat cells. After 1 h incubation of either DNP-HSA or AgNPs at 37°C, p-nitrophenyl-N-acteyl-
β-D-glucopyranoside (≥ 98%) was added to cell supernatants and lysates for 90 min as a 
chromogenic substrate for N-acetyl-β-D-hexosaminidase (Sigma-Aldrich) (Brown et al., 2007). 
The reaction was stopped with 0.4 M glycine. Optical density was measured at 405 nm using a 
Synergy™ HT Multi-Mode Microplate Reader (BioTek Instruments, Inc, Winooski, VT). β-
hexosaminidase release was expressed as the percentage of total cell content after subtracting 
background release from unstimulated cells. All experiments were performed in triplicate from 3–
6 individual batches of mature mast cells. Each batch of mast cells was grown from femoral bone 
marrow of 2 mice. 
Lamp2 Expression  
3x105 cells were treated with AgNPs, spun at 1200 rpm for 5 min and then suspended in 
200 µl of PBS. Cells were then spun at 300 rpm for 5 min onto a glass slide using a Cytospin IV 
(Shandon Scientific Ltd., Cheshire, UK). Cells were then fixed in a 2% paraformaldehyde solution 
for 10 min at 37° C, washed with PBS and blocked in 0.1% Tween + 1% BSA for 30 min at 37° 
C. After removing blocking solution, a Lamp2 antibody (eBioscience Inc., San Diego, CA, USA) 
conjugated to FITC was added to slides at a dilution of 1:100 and incubated overnight at 4° C. 
Following incubation the slide was washed 3 times with PBS and mounted with DAPI staining 
ProLong® (Life Technologies, Carlsbad, CA).  Cells were then assessed using a fluorescent 
microscope (Cytoviva) to evaluate Lamp2 expression. 
Osteopontin Measurement  
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 2.5x105 cells were pretreated with or without the scavenger receptor B1 (SR-B1) inhibitor 
Blt2 at a concentration of 50 µM. After 30 min, cells exposed to AgNPs at concentration of 50 
µg/ml for for 24 h. OPN levels were measured in cell supernatant using a DuoSet ELISA kit (R&D 
Systems, Minneapolis, MN) in accordance with the manufacturer’s instructions. Values are an 
average of three replicates and reported as pg/mL. All experiments were performed in triplicate 
from 3 individual batches of mature mast cells. Each batch of mast cells was grown from femoral 
bone marrow of 2 mice. 
Statistical Analyses  
All data are presented as mean ± SEM and were analyzed by one-way ANOVA, with 
differences between groups assessed using Bonferroni post hoc tests. Graphs and analysis were 
performed using GraphPad Prism 5 software (GraphPad, San Diego, CA). Differences were 





Hydrodynamic size and zeta potential were measured by dynamic light scattering in 
HEPES buffer that was used for the subsequent mast cell degranulation studies (Table 2.1). The 
hydrodynamic and TEM sizes were similar for the P20, C20, P110, and C110 samples since they 
are spherical nanoparticles unlike the P550, P850, and wires that have different morphology. It 
should be noted that the traditional dynamic light scattering technique is based on Einstein-Stokes 
relation that is apt only for spherical particles and may only provide an order of magnitude estimate 
for individual dimensions in different direction for non-spherical shapes. In our case, the 
hydrodynamic size for P550, P850, and wires in HEPES buffer clearly confirms their nanosize 
while TEM provides more accurate size data. We found that the C20 AgNPs have the smallest 
hydrodynamic size with an average of 26.61 nm while the Ag nanowires have largest 
hydrodynamic size with an average of 315 nm (n=3/group). All AgNPs had a negative zeta 
potential with the citrate suspended AgNPs displaying the most negative surface charge as 
compared to PVP suspended AgNPs. The shape and size was further confirmed by TEM images 
of AgNPs (Figure 2.1). 
AgNP Uptake by Mast Cells 
Enhanced darkfield imaging of BMMCs following 1 h exposure to AgNPs showed 
interaction and presence of particles within and on the surface of cells (Figure 2.2). The surface 
bound and internalized particles were quantified using ICP-MS analysis (n=3/group) (Figure 2.3). 
Following AgNP exposure for 1 h, we found that significant uptake of AgNPs by mast cells 
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occurred in all treated samples. However, pretreatment with the SR-B1 inhibitor significantly 
decreased the cellular uptake of P20 and P110 (Figure 2.3). 
AgNP Induced Mast Cell Degranulation 
Following a 1 h exposure to AgNPs, BMMC degranulation was evaluated through 
measuring β-hexosaminidase release into the supernatant (n=3/group) (Figure 2.4). P20 and C20 
caused significant BMMC degranulation at concentrations of 25 and 50 µg/ml (Figure 2.4A). P110 
and C110 were not found to cause BMMC degranulation compared to control (Figure 2.4B). P550 
and P850 caused significant mast degranulation at all concentrations (Figure 2.4C). Exposure to 
Ag nanowires led to an increase in BMMC degranulation at concentrations of 12.5, 25, and 50 
µg/ml (Figure 2.4D).  P850 did not demonstrate a concentration-dependent increase in 
degranulation as shown by P20, C20, and Ag nanowires. To determine whether AgNP or Ag+ ions 
were responsible for degranulation, BMMCs were exposed to Ag+ ions for 1 h and degranulation 
was evaluated.  Exposure to Ag+ ions was not found to induce mast degranulation (Figure 2.4E). 
To evaluate the role of SR-B1 in degranulation following AgNP exposure, BMMCs were 
pretreated with or without Blt2 at concentration of 50 µM for 30 min. In this experiment, we 
evaluated only AgNPs that elicited significant BMMC degranulation (>50%). Following a 1 h 
exposure to AgNPs at a concentration of 50 µg/ml, β-hexosaminidase was assessed. The 
degranulation of BMMCs exposed to P20, C20, and Ag nanowires was significantly reduced by 
pretreatment with the SR-B1 inhibitor Blt2 (Figure 2.4F). 
To confirm our observation of AgNP directed BMMC degranulation measured by β-
hexosaminidase release, we assessed lysosome-associated membrane proteins 2 (Lamp2) 
expression in BMMCs following AgNPs exposure (Figure 2.5). The expression of Lamp2 
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following exposure to the various AgNPs was found to match the results of the β-hexosaminidase 
assay. Lamp2 expression as measured by immunofluorescence (green) was observed in BMMCs 
exposed to P20, C20, P550, and Ag nanowires while expression of Lamp2 was low in samples 
treated with P110, C110, and P850 (Figure 2.5). 
Osteopontin Release Following AgNP Exposure 
Osteopontin (OPN) levels were measured in the supernatant following exposure to AgNPs 
(n=3/group) in order to assess AgNP-induced mast cell activation. Mast cells were pretreated with 
or without Blt2 at concentration of 50 µM for 30 min. Following inhibitor pretreatment, BMMCs 
were exposed to AgNPs at a concentration of 50 µg/ml for 24 h. OPN levels were increased in the 
supernatant of BMMCs exposed to all types of AgNPs except for P110 (Figure 2.6).  Pretreatment 
with Blt2 was found to decrease OPN levels in the supernatant of BMMCs exposed to all types of 
AgNPs (Figure 2.6). 
Pharmacological Inhibition of Mast Cell Activation by AgNPs 
To begin to understand potential mechanisms of AgNP-induced degranulation we 
pretreated cells with imatinib, a tyrosine kinase inhibitor. BMMCs were pretreated with or without 
imatinib for 30 min at concentrations of 0.1, 1, 10, and 100 µM and then exposed to C20 at 50 
µg/ml for 1 h (n=3/group).  Following C20 exposure, β-hexosaminidase release was increased as 
observed previously, however, treatment with imatinib resulted in a concentration-dependent 




Currently we lack sufficient knowledge regarding the ability of these NPs to induce and/or 
promote allergic disease.  Recent studies by our laboratory have demonstrated that mast cells 
contribute to the inflammation and pathology induced following cerium oxide and carbon-based 
NP exposure in animal models (Katwa et al., 2012, Wingard et al., 2011). Our current study 
investigated the direct interactions of physicochemically distinct AgNPs on mast cell activation 
and degranulation.  Further, we evaluated the role of SR-B1 in these AgNP-induced mast cell 
responses.  In summary, this study determined that P20, C20, nanoplates and Ag nanowires could 
directly induce the degranulation of mast cells.  Further this degranulation was driven by particle 
interactions through the SR-B1 receptor and not the result of dissolution of Ag+ ions.  Through 
evaluation of our data we have provided insight into some of the physicochemical properties of 
NPs which could likely lead to adverse mast cell responses. 
Our study evaluated mast cell responses to AgNPs that differed based upon size, shape, 
and surface coating.  These AgNPs were specifically selected for the determination of NP 
physicochemical properties, which could influence interactions with mast cells and may initiate or 
promote allergic responses.  Specifically, we selected four spherical AgNPs that differed based on 
size (20 nm or 110 nm) and surface coating (PVP or Citrate).  Further we selected two plate-shaped 
AgNPs, which differed based upon size and resonance (P550 or P850) and were coated with PVP.  
Lastly we selected Ag nanowires that differed vastly from the other AgNPs based on their needle-
like shape and high aspect ratio. Through the use of these selected AgNPs we were able to 
determine mast cell responses in terms of specific AgNP characteristics. 
The internalization of NPs by mast cells has been reported in different studies. For instance 
silicon dioxide (SiO2) and titanium dioxide (TiO2) was found to be internalized by mast cells and 
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localized in the secretory granules (Maurer-Jones et al., 2010). Following internalization by mast 
cells, NPs have been reported to induce or suppress mast degranulation. For instance, mast cells 
have been shown to internalize fullerenes through nonspecific endocytosis causing an inhibition 
of degranulation (Ryan et al., 2007). In contrast, gold NPs have been reported to induce mast cell 
degranulation following internalization that was dependent on size, exposure time, and 
concentration (Huang et al., 2009, Marquis et al., 2009). Overall NP internalization and subcellular 





All of our selected AgNPs were found to be internalized following exposure albeit to 
varying degrees based upon their physicochemical differences. C20 and C110 were determined to 
have a more highly negative zeta potential compared to PVP suspended spherical AgNPs.  
However, PVP suspended particles were cell associated to a greater degree when compared to 
citrate suspended particles of the same size and shape.  Such an observation concurs with the fact 
that PVP stabilized AgNPs are more prone to surface oxidation and subsequently interact strongly 
with biomolecules (e.g., serum albumin) (Podila et al., 2012). This suggests that uptake of these 
spherical AgNPs is not completely driven by charge but also the identity of the surface coating. 
Interestingly P110, P550, and Ag nanowires were found to have similar surface charges (-27.3, -
29.6, -25.9 mV respectively) and the same PVP surface coating, however each were internalized 
at varying amounts.  This demonstrates that uptake is also influenced by size and/or shape of the 
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NP. This was not unexpected as the influence of size and shape of NPs has been reported to play 
critical role in cellular uptake (Miethling-Graff et al., 2014). Lastly, P850 AgNPs were taken up 
more readily than P550 AgNPs.  These plates have the same surface coating, shape but differ based 
upon size suggesting that size is a major factor in their internalization.  Internalization of our 
selected AgNPs by mast cells is a complex process that seems to be dependent on a combination 
of physicochemical properties. 
The primary objective of this study was to evaluate NP characteristics, which could 
possible promote allergic immune responses through direct interaction with mast cells resulting in 
degranulation and the release of inflammatory mediators.  Exposure to spherical 20 nm AgNPs 
was found to induce mast cell degranulation whereas spherical 110 nm AgNPs did not.  Further, 
exposure to P550 was found to induce degranulation to a greater degree than P850. Even though 
Ag nanowires and P110 spherical AgNPs existed with a similar surface charge and coating, Ag 
nanowires were found to induce degranulation whereas the spherical AgNPs did not. NPs with 
high aspect ratio such as (MWCNTs) have been reported to cause lysosomal damage and induce 
inflammasome activation that was dependent on NP length (Hamilton et al., 2013, Li et al., 2013a). 
Furthermore, TiO2 NPs with fiber structure have been found to induce cytotoxicity, reactive 
oxygen species (ROS) generation, increased expression of inflammatory cytokines, lysosomal 
damage, and induction of inflammasome activation (Li et al., 2013a, Hamilton et al., 2013). While 
in the present study the Ag nanowires reduced cellular uptake, this shape of AgNPs led to mast 
cell degranulation likely due to the high aspect ratio of the material (Champion et al., 2007, 
Champion and Mitragotri, 2006, Harris and Dalhaimer, 2012, Sunshine et al., 2014, Sharma et al., 
2010). Overall these findings support a role for size and possibly shape in the degranulation 
response likely mediated through cell surface receptor recognition. Similar results have reported 
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that mast cells interact differently with different size and shape of same nanomaterial.  For 
instance, carbon based NPs have been reported to induce mast cell activation as reported with 
multi-walled carbon nanotubes or can suppress mast cell activation as it has been reported with 
single-walled carbon nanotubes and fullerene C60 (Katwa et al., 2012, Umemoto et al., 2014, 
Huang et al., 2009, Ryan et al., 2007).  Based on our current findings, mast cell degranulation is 
not entirely dependent on internalization of the NP.  Specifically, both the citrate and PVP 
suspended spherical 110 nm AgNPs, while internalized by mast cells, were not found to induce 
degranulation. In comparison, the C20 AgNPs although not internalized to the same degree as the 
PVP suspended 20 nm AgNPs induce equivalent degranulation. Such an observation is intriguing 
in that the dissolution of C20 is expected to be much slower than P20 eliminating Ag+ as a possible 
cause for degranulation (Kittler et al., 2010). These findings are consistent with other reports that 
the uptake of NPs by mast cells causes a variety of mast cell responses including the suppression 
of mast cell degranulation and decreased reactive oxygen species generation while some have been 
shown to induce degranulation (Umemoto et al., 2014, Ryan et al., 2007, Dellinger et al., 2010). 
Our findings suggest cellular signaling initiated by size-dependent NP-cell surface receptor 
interactions facilitated mast cell degranulation that is not completely driven by NP uptake.  
Ultimately, through our assessment of physicochemically diverse AgNPs, we have demonstrated 
that some NPs can directly interact with mast cells inducing degranulation, which could induce 
and/or promote allergic disease in vivo. 
Osteopontin is a secreted phosphoglycoprotein expressed by a variety of cell types and has 
been reported as a risk predictor in various diseases including cardiovascular and cancer such as 
mesothelioma that associated with asbestos exposure (Yang et al., 2008, Berezin and Kremzer, 
2013, Pass and Carbone, 2009) . Mast cell activation following NP exposure leads to the release 
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different cytokines such as OPN and has been reported to be up-regulated following cerium oxide 
exposure in mice (Wingard et al., 2011). In our current study, we found that OPN is released from 
mast cells following exposure to all of the selected AgNPs even when NP exposures resulted in 
limited or no degranulation.  These findings are similar to previous research conducted in our 
laboratory demonstrating that silica exposure also results in cytokine production with limited mast 
cell degranulation (Brown et al., 2007).  This demonstrates that the de novo production and release 
of cytokines from mast cells following particle exposure may involve separate cell signaling 
pathways compared to degranulation. Our current study also demonstrates that inhibition of the 
scavenger receptor, SR-B1, reduces the production and release of OPN.  Our findings also suggest 
that while certain NPs do not induce mast cell degranulation, these particles can significantly alter 
the release of mast cell derived cytokines thereby contributing to an inflammatory response absent 
of mast cell degranulation.  Overall, these findings illustrate that further studies are needed to 
elucidate mast cell signaling mechanisms. 
SR-B1 is well known for its role in the transport of lipid molecules into cells (Krieger and 
Herz, 1994, Landschulz et al., 1996, Rigotti et al., 1997a). However, it has also been reported that 
SR-B1 can recognize and bind to other molecules, specifically those that are negatively charged 
(Catanese et al., 2013, Baranova et al., 2005, Murao et al., 1997). In this study, all AgNPs carried 
a negative charge therefore interaction between SR-B1 and AgNPs was expected.  Inhibition of 
SR-B1 was found to reduce the uptake of P20, P110, C110, and P850 AgNPs whereas uptake of 
other AgNPs was unaffected.  Due to the range of surface charges exhibited by these AgNPs, SR-
B1 recognition and SR-B1 mediated uptake does not appear to be strictly based on NP surface 
charge.  Treatment with an SR-B1 inhibitor (Blt2) was found to reduce mast cell degranulation 
following exposure to P20, C20, P550, and Ag nanowires.  However, SR-B1 inhibition did not 
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reduce degranulation of mast cells induced by P550 AgNPs or Ag nanowires to the same extent as 
P20 or C20 AgNPs, which were reduced to control levels.  Comparatively, P20 and C20 AgNPs 
have a greater negative Zeta potential and smaller size than P550 and Ag nanowires. These findings 
suggest that exposure to P20 and C20 AgNPs induces mast cell degranulation through SR-B1 
whereas P550 AgNPs and Ag nanowires induce degranulation primarily via other surface receptors 
or pathways.  Overall our use of an SR-B1 inhibitor demonstrates that mast cell responses to AgNP 
exposure are to some degree mediated through SR-B1. These findings have safety implications for 
the design of NPs that do not interact with scavenger receptors may reduce the likelihood of 
unintended allergic responses mediated through mast cells. 
Mast cells can be activated through a variety of cell-surface receptor facilitated 
mechanisms including interactions with SR-B1, FCεRI, or c-Kit.  Activation of these receptors 
leads to increased calcium flux, tyrosine kinase phosphorylation, and ultimately mast cell 
degranulation (Zhu et al., 2009, Canton et al., 2013) Imatinib is a therapeutic agent that inhibits 
the phosphorylation of tyrosine kinases thereby inhibiting downstream mast cell degranulation. 
We determined in this study, that imatinib treatment reduces mast cell degranulation following 
exposure to C20 AgNPs thereby demonstrating that the NP-induced mast cell degranulation can 
be therapeutically inhibited.  These findings also suggest that there are downstream cell signaling 
events, which occur following NP cell-surface receptor interactions that require further 
investigation.  These cellular signaling pathways are likely differentially induced based on NP 




This study demonstrates that mast cells can be directly activated by NPs, which may 
ultimately induce and/or promote an allergic immune response.  Further, NP-induced mast cell 
degranulation is related to the physicochemical properties of the NP such as shape, size, and 
surface coating.  This study implicates a role for SR-B1 in the degranulation of mast cells by NPs 
and suggests that possible allergic responses to NPs can be therapeutically treated by inhibition of 
tyrosine kinase phosphorylation.  Future research needs to be performed to understand cell-
signaling pathways, which control cytokine production and degranulation.  Through an 
understanding of these mechanisms NPs can be formulated and utilized for numerous applications 














Figure 2.1 Transmission electron microscopy (TEM) of AgNPs 
Representative TEM images demonstrating AgNP shape and size. AgNPs of differing size and 
shape were evaluated including spherical 20 nm AgNPs suspended in either polyvinylpyrrolidone 
(P20) or citrate (C20), spherical 110 nm AgNPs suspended in either polyvinylpyrrolidone (P110) 
or citrate (C110), Ag plates suspended in polyvinylpyrrolidone of either 550 nm resonance (P550) 















Figure 2.2 Enhanced Darkfield Images of Control or AgNP Treated Bone Marrow-Derived 
Mast Cells (BMMCs) 
Representative enhanced darkfield images of control or AgNP treated bone marrow-derived mast 
cells (BMMCs). AgNPs of differing sizes and shapes were evaluated including spherical 20 nm 
AgNPs suspended in either polyvinylpyrrolidone (P20) or citrate (C20), spherical 110 nm AgNPs 
suspended in either polyvinylpyrrolidone (P110) or citrate (C110), Ag plates suspended in 
polyvinylpyrrolidone of either 550 nm resonance (P550) or 850 nm resonance (P850), and Ag 








Figure 2.3 ICP-MS Measurement of AgNP Uptake by Bone Marrow-Derived Mast Cells 
(BMMCs) 
ICP-MS measurement of AgNP uptake by bone marrow-derived mast cells (BMMCs). Cells were 
pretreated with or without the scavenger receptor B1 (SR-B1) inhibitor Blt2 prior to AgNPs 
exposure. Values are expressed as mean ± SEM (n=3/group). * Significant difference from control 
group (p ≤ 0.05). #Significant difference of Blt2 pretreated group compared to Blt2 untreated group 








Figure 2.4 Evaluation of Mast Cell Degranulation following AgNPs exposure 
Mast cell degranulation was evaluated by measuring release of β-hexosaminidase into the 
supernatant 1 h following AgNP exposure. A) Bone marrow-derived mast cell (BMMC) 
degranulation following exposure to spherical polyvinylpyrrolidone (PVP) coated (red) or citrate 
coated 20 nm  (blue) AgNPs. B) BMMC degranulation following exposure to spherical PVP coated 
(green) or citrate coated 110 nm (purple) AgNPs. C) 550 nm or 850 nm resonant AgNP plates. D) 
BMMC degranulation following exposure to PVP coated Ag nanowires. E) BMMC degranulation 
following exposure to Ag+ ions. F) BMMC degranulation of samples pretreated with or without 
the scavenger receptor B1 (SR-B1) inhibitor Blt2. Values are expressed as mean ± SEM 
(n=3/group). *Significant difference from controlled group (p ≤ 0.05). #Significant difference of 



















Figure 2.5 Evaluation of AgNPs-induced Lysosome-Associated Membrane Protein 2 
(Lamp2) Expression 
Lysosome-associated membrane protein 2 (Lamp2) expression (green) in bone marrow-derived 
mast cells (BMMCs) following AgNP exposure. BMMCs were collected 1 h following AgNP 
exposure, washed, spun onto glass slides and immunofluorescently stained with DAPI to identify 














Figure 2.6 Measurement of Osteopontin (OPN) level in Bone Marrow-Derived Mast Cells 
Following AgNPs Exposure 
Osteopontin (OPN) levels were measured in supernatants by ELISA. Bone marrow-derived mast 
cells (BMMCs) were pretreated with or without the scavenger receptor B1 (SR-B1) inhibitor Blt2 
before AgNPs exposure. Values are expressed as mean ± SEM (n=3/group). * Significant 
difference from controlled group (p ≤ 0.05). #Significant difference of Blt2 pretreated group 













Figure 2.7 Pharmacological Inhibition of Mast Cell Activation by AgNPs 
Bone marrow-derived mast cell (BMMC) degranulation was evaluated by measuring release of β-
hexosaminidase 1 h following exposure to 50 µg/ml of 20 nm citrate coated AgNPs (C20). Cells 
were pretreated with or without imatinib for 30 min at concentration of 0.1, 1, 10, 100 µM. 
*Significant difference from controlled group (p ≤ 0.05). #Significant difference of imatinib 


















CHAPTER 3: Scavenger Receptor B1 Facilitates Macrophage Uptake of Silver 
Nanoparticles and Cellular Activation 




Due to increased use of silver nanoparticles (AgNPs) for their antimicrobial activity 
concerns have risen regarding potential adverse human health effects. Scavenger receptor B1 (SR-
B1), a major receptor for high-density lipoprotein (HDL), is expressed by macrophages and has 
also been reported to play a role in recognition of negatively charged particles. We therefore 
hypothesized that SR-B1 mediates macrophage uptake of AgNPs and inflammatory activation. To 
test this hypothesis we exposed a mouse macrophage cell line RAW264.7 (RAW) and bone 
marrow-derived macrophages (BMDM) to 20 nm citrate-suspended AgNPs. To verify the role of 
the SR-B1 receptor we utilized a SR-B1 inhibitor (Blt2). In vitro studies demonstrated uptake of 
AgNPs and HDL coated AgNPs by macrophages which was significantly reduced following 
pretreatment with Blt2. Inflammatory cytokine arrays revealed that macrophages exposed to 
AgNPs up-regulated expression of Tnf-α, Oncostatin m (OSM), Ccl4, Il17f, Ccl7, and Ccl2, 
whereas Il16 was found to be downregulated. Macrophage activation was observed following 
AgNP and HDL coated AgNP exposure as measured by OSM protein production and increased 
surface expression of CD86.  These markers of activation were reduced with Blt2 pretreatment. 
The in vitro findings were confirmed in vivo through pulmonary instillation of AgNPs in mice.  
Pulmonary instillation of AgNPs resulted in a recruitment of inflammatory cells that were reduced 
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in SR-B1 deficient mice or following Blt2 pretreatment. This study suggests that SR-B1 plays a 
major role in cellular recognition of AgNPs and the induction of cell responses that could 




















The use of nanoparticles (NPs) has increased in the last decade due to their unique physical 
and chemical properties. Specifically, silver nanoparticles (AgNPs) have attracted high attention 
due to their antimicrobial and antifungal properties, which have led to their extensive usage in 
water filters, biomedical products, surgical tools, and wound dressing (Nocchetti et al., 2013, Dong 
et al., 2012, Levard et al., 2013). These incorporated AgNPs may potentially leach out of consumer 
products as Ag or Ag+ ions thereby posing a potential human health risk (Christensen et al., 2010). 
The use of AgNPs as drug carriers or in wound dressings and surgical implants could lead directly 
to their entrance into systemic circulation thereby distributing to a variety of organs including the 
liver, spleen, kidney and lungs (Rahman et al., 2009, Tang et al., 2009). Specifically, exposure to 
AgNPs has been found to induce hepatotoxicity and pulmonary inflammation (Tiwari et al., 2011, 
Sung et al., 2008). In addition, AgNPs have been reported to interact with macrophages and cause 
cytotoxicity through the generation of reactive oxygen species (Nishanth et al., 2011, Carlson et 
al., 2008). 
Macrophages are well-known to be one the primary innate immune cells to remove foreign 
particles and pathogens through phagocytosis; scavenge apoptotic cells and cellular debris; and 
are involved in tissue remodeling (Gordon and Taylor, 2005, Wynn and Barron, 2010). 
Macrophages express various types of scavenger receptors that help in the removal of dead cells 
and foreign particles leading to cellular activation and the production of a variety of mediators that 
promote inflammation (Gordon and Taylor, 2005). It has been reported that macrophages readily 
interact with and phagocytose a number of different types of NPs such as zinc oxide, titanium 
dioxide, and AgNPs (Triboulet et al., 2014, Zhang et al., 2013, Singh and Ramarao, 2012).  
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Specifically, scavenger receptors have been found to mediate the uptake of AgNPs by 
macrophages and facilitate the apoptotic response (Singh and Ramarao, 2012). 
Scavenger receptors were originally defined by their ability to bind modified low-density 
lipoprotein (LDL), however they recently have been found to interact with a variety of other 
substances including pathogens and foreign objects (Goldstein et al., 1979). The scavenger 
receptor family is subdivided, based on their structures and functions, into 8 classes designated A 
to I (Krieger, 1997, Murphy et al.). Scavenger receptor B1 (SR-B1) is a multi-ligand receptor that 
binds to high density lipoprotein (HDL) and other modified LDL molecules therefore facilitating 
lipid molecule uptake by cells (Krieger and Herz, 1994, Landschulz et al., 1996, Rigotti et al., 
1997a, Rigotti et al., 1997b). SR-B1 is expressed on a variety of cell types including epithelial, 
endothelial, and macrophages (Duncan et al., 2002, Valacchi et al., 2011, Rigotti et al., 1997a).  
While the role of scavenger receptor A (SR-A) in NP recognition has been reported, little is known 
on how SR-B1 contributes to NP uptake and cellular responses (Orr et al., 2011, Chao et al., 2013, 
Aldossari et al., 2015). 
In the current study, we hypothesized that SR-B1 on macrophages mediates uptake of 
AgNPs and subsequent cellular activation.  To address this hypothesis, we utilized a mouse 
macrophage cell line RAW264.7 (RAW) and an inhibitor to SR-B1 to examine 20 nm AgNP 
uptake using inductively coupled plasma mass spectrometry (ICP-MS), flow cytometry and 
enhanced darkfield hyperspectral microscopy.  In addition, we examined macrophage activation 
(cytokine production and CD86 expression) following exposure to AgNPs in the presence or 
absence of an SR-B1 inhibitor.  Lastly, we performed an in vivo experiment in SR-B1-/- mice to 
examine macrophage uptake and inflammation following a pulmonary instillation of AgNPs.  
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Materials and Methods 
Silver Nanoparticles and Protein Corona Formation   
AgNPs with a diameter of 20 nm were procured from NanoComposix (San Diego, CA) by 
the NIEHS Centers for Nanotechnology Health Implications Research (NCNHIR) in a suspension 
of citrate (C6H5O7
3-) at a concentration of 1 mg/ml. To form the protein corona (PC), AgNPs were 
incubated at 10°C for 8 h on a rotator in the presence HDL (Sigma-Aldrich, St. Louis, MO, USA) 
at a concentration of 2.5 mg/ml.  After incubation AgNPs were centrifuged at 14,000 rpm (20,817 
g) for 10 min at 4°C and resuspended to 1 mg/ml with DI water. 
Silver Nanoparticle and Protein Corona Characterization  
The size and shape of the AgNPs were confirmed via transmission electron microscopy 
(TEM, Hitach H7600). Size distribution analysis was performed using the freeware software 
Image J. A minimum of 100 particles per sample were counted by randomly surveying the entire 
TEM grid from multiple high magnification images. Image J was used to determine both area and 
Feret diameters (the greatest distance between two points on an objects boundary).  The 
hydrodynamic size and zeta potentials (ZetaSizer Nano, Malvern) of AgNPs and HDL coated 
AgNPs were characterized in DI water. All measurements were performed with 3 individuals 
samples at a concentration of 50 µg/ml.  Hyperspectral enhanced darkfield microscopy (Cytoviva, 
Auburn, AL) was utilized to characterize spectral shifts following association of HDL. Particles 
were loaded onto premium clean microscope slides and mean spectrums were created utilizing 
pixels with an intensity greater than 1000.  Mean spectrums were then compared to AgNPs without 
HDL to determine changes due to the association of HDL.  A red shift in spectrum following 
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incubation with protein is indicative of PC formation.  These mean spectra were later used to 
identify AgNPs within macrophages to confirm uptake. 
Cell Culture   
Mouse macrophages (RAW264.7) were obtained from the American Type Culture 
Collection (ATCC) and cultured in DMEM media containing 10% FBS and 1.0% penicillin-
streptomycin solution.  Macrophages were maintained in flasks under standard conditions of 37°C 
and 5% CO2.  Bone marrow-derived macrophages (BMDM) were cultured from femoral marrow 
cells of C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME). Cells were cultured in RPMI 1640 
medium supplemented with 10% FBS, 100 U/ml penicillin-streptomycin, 1.0 mM sodium 
pyruvate, and 0.0035% 2-mercaptoethanol. Bone marrow cells were seeded in flasks at 3 x 107 
cells/T75 in 20 ml of media overnight at 37°C for stromal cell elimination. At day 2, media was 
removed from cells and replaced with 20 ml of fresh media which contained 10 ng/ml macrophage 
colony-stimulating factor (M-CSF) (10 µg/ml stock, R&D). At day 4-5, an additional 5 ng/ml M-
CSF was added to cells. At day 7-8, half of the media was replaced with fresh media and 5 ng/ml 
of M-CSF was added. This procedure of macrophage differentiation results in cells ready to use 
for experimentation between days 7 and 10 depending on health and confluency. All animal 
procedures were conducted in accordance with the National Institutes of Health guidelines and 
approved by the University of Colorado Denver Institutional Animal Care and Use Committee.  
All animals were treated humanely and with regard for alleviation of suffering. 
Assessment of AgNP Cytotoxicity   
RAW cells were grown to 90% confluency in 96 well plates (Costar) and were exposed to 
(0, 6.25, 12.5, 25, or 50 µg/ml) of AgNPs and AgNPs coated with HDL for 3 and 6 h in serum-
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free media.  The concentrations evaluated were selected based on previous in vitro examination of 
other nanoparticles (Xia et al. 2013).  Changes in cell viability were assessed via the MTS assay 
(Promega, Madison, WI, USA) via manufacturer’s instructions using a spectrophotometer (BioTek 
Synergy HT, BioTek, Winooski, VT, USA).  Based on this dose response study a concentration of 
50 µg/ml was utilized for all subsequent in vitro experiments. All experiments were performed in 
triplicate from 4 to 5 individual batches of RAW cells. 
Cellular Uptake of Silver Nanoparticles 
 For ICP-MS determination of cellular uptake, 3x105 RAW cells were pretreated for 30 min 
with or without an SR-B1 inhibitor 2-(2-butoxyethyl)-1-cyclopentanone thiosemicarbazone (Blt2) 
(Chembridge Corp., San Diego, CA, USA) at 50 uM and then exposed to AgNPs at a concentration 
of 50 µg/ml for 2 h.  Following exposure, cells were washed three times with PBS to remove 
excess AgNPs. All samples were dissolved in 6 ml of 2% HNO3.  Subsequently, the Ag cellular 
concentration was determined by ICP-MS (X series II, Thermo Scientific) with a detection limit 
of 0.05 ppb using an internal standard containing Li, Y, and In. To assess AgNP uptake by flow 
cytometry, RAW cells were grown to 90% confluency in 24 well plates (Costar) and were 
pretreated for 30 min with either serum-free media (control) or Blt2 at 50 μM.  Cells were then 
exposed to AgNPs at 50 μg/ml for 2 h.  Following exposure, cells were washed with PBS and 
detached with 250 μl of trypsin.  Trypsin was neutralized with an equal volume of media containing 
serum and macrophages were collected.  Changes in uptake were assessed by alterations in side 
scatter shift through flow cytometry (Accuri C6 Flow Cytometer, BD Biosciences, San Jose, CA, 
USA). All experiments were performed in 3 individual batches of RAW cells 
Enhanced Darkfield Hyperspectral Imaging     
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RAW cells (3x105) were grown on chamber slides and exposed to AgNPs at a 
concentration of 50 µg/ml for 2 h.  Cells were then fixed in 2% paraformaldehyde solution for 10 
min at 37oC, washed with PBS three times and mounted with ProLong® (Life Technologies, 
Carlsbad, CA). Cells were then qualitatively assessed by enhanced darkfield microscopy 
(Cytoviva, Auburn, AL) for uptake of AgNPs. Mean spectral profiles used to characterize AgNPs 
were utilized for spectral mapping of AgNPs within cells. Spectral mapping identifies pixels in 
images of AgNP-exposed macrophages that positively match the spectral profiles of AgNPs alone 
confirming the identity of the particle within the cell.  Pixels that positively match AgNP spectral 
profiles are identified by being colored red in images. 
PCR Array  
A mouse inflammatory cytokine PCR array was utilized to identify markers of macrophage 
activation following AgNP exposure. BMDMs were grown and exposed to 50 ug/ml of AgNPs for 
2 h and collected in Trizol. Total RNA was isolated using Direct-zol RNA MiniPrep (Zymo 
Research Corp., Irvine, CA, USA) via manufacturer’s instructions and quantified via Nanodrop 
(Nanodrop 2000c Spectrophotometer, Thermo Scientific).  cDNA synthesis was performed using 
RT² SYBR Green Mastermix and the RT2 First Strand Kit (SABiosciences, Frederick, MD, USA). 
RT2 Profiler PCR Array Systems (Cat# PAMM-011Z, SABiosciences; Frederick, Maryland, USA) 
of 84 genes encoding key inflammatory cytokines and chemokines were used. 96 well plates were 
prepared according to manufacturer’s instructions and using a StepOnePlus Real-Time PCR 
System (ABI, Foster City, CA, USA)). The data analysis was based on the ΔΔCt method with 
normalization to glyceraldehyde 3-phosphate dehydrogenase. A web-based integrated PCR array 
expression analysis suite provided by SaBiosciences was used for data analysis. All experiments 
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were performed in triplicate from 6 individual batches of BMDM cells.  Data from all 84 genes is 
available within Supplemental Table 1. 
Oncostatin M Measurement   
OSM levels were measured in the cell supernatant of 2.5x105 RAW cells that were 
pretreated for 30 min with either serum-free media or Blt2 at 50 μM to evaluate the role of SR-B1 
and then treated with AgNPs for 24 h.  OSM levels were measured in the supernatant using a 
DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer’s 
instructions. Values are an average of experiments that were performed in triplicate from 3 
individual batches of RAW cells and reported as pg/mL. 
CD86 Expression   
RAW cells were grown to 90% confluency in 24 well plates (Costar) and pretreated for 30 
min with either serum-free media or Blt2 at 50 μM. Cells were then exposed to AgNPs at 50 μg/ml 
for 6 h. Following exposure, cells were washed with PBS and detached with 250 μl of trypsin.  
Trypsin was neutralized with an equal volume of media with serum and cells were collected. Cells 
then were washed twice with staining buffer (Pharmingen™, BD Biosciences) and then suspended 
in 100 μl of staining buffer and 2 μl of Fc receptor antibody (eBioscience Inc., San Diego, CA, 
USA)  for 10 min on ice. A CD86 antibody conjugated to PerCp-Cy5.5 (eBioscience Inc., San 
Diego, CA, USA) was then added at a concentration of 1:100 and incubated for 30 min at room 
temperature in the dark. Following incubation, cells were washed twice with staining buffer and 
finally suspended in 500 μl of staining buffer and 5x103 events were assessed by flow cytometry 





C57BL/6J and Scarb1-/- (SR-B1-/-) mice were acquired from Jackson Laboratories (Bar 
Harbor, ME, USA) at 4–10 weeks of age and breeding colonies were maintained at the University 
of Colorado. C57BL/6J mice were pretreated with PBS or 250 μg/kg body weight of Blt2 for 30 
min prior to AgNP aspiration.  C57BL/6 mice (n=3) (with or without Blt2 pretreatment) and SR-
B1−/− mice (n=3) were exposed by oropharyngeal aspiration to AgNPs at a concentration of 2 
mg/kg body weight. Two hours post-exposure, mice underwent in situ right lung bronchoalveolar 
lavage (BAL). The right lung was lavaged four times with the same aliquot of ice-cold Hanks 
balanced salt solution (HBSS) at 26.25 ml/kg body weight.  Cells were then spun down onto 
microscope slides using a Cytospin IV (Shandon Scientific Ltd., Cheshire, UK). The collected 
bronchoalveolar lavage fluid (BALF) was used to qualitatively assess macrophage uptake by 
enhanced darkfield imaging (Cytoviva). Similar to the previous in vitro experiment, AgNPs were 
positively identified in macrophages via spectral mapping.  In a separate experiment, C57BL/6J 
mice (n=3) pretreated with PBS or Blt2 for 30 min and SR-B1−/− (n=3) mice were exposed via 
oropharyngeal aspiration to AgNPs at a concentration of 2 mg/kg.  BALF was collect 24 h post-
exposure from the right lung for differential cell counts. The right lung was lavaged four times 
with the same aliquot of ice-cold HBSS at 26.25 ml/kg body weight. A total cell count on BALF 
samples was then performed and 20,000 cells from each sample were loaded on slides using a 
Cytospin IV (Shandon Scientific Ltd., Cheshire, UK).  Slides were then prepared with a three-step 
hematology stain (Richard Allan Scientific, Kalamazoo, MI, USA) and differential cell counts 
were determined by morphology with evaluation of 300 cells per slide. All animal procedures were 
conducted in accordance with the National Institutes of Health guidelines and approved by the 
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University of Colorado Denver Institutional Animal Care and Use Committee. All animals were 
treated humanely and with regard for alleviation of suffering. 
Statistical Analyses 
 All data are presented as mean ± SEM and were analyzed by one-way or two way 
ANOVA, with differences between groups assessed using Bonferroni post hoc tests. Graphs and 
analysis were performed using GraphPad Prism 5 software (GraphPad, San Diego, CA). 




Silver Nanoparticle Characterization 
Hydrodynamic size and zeta potential were measured using a ZetaSizer Nano (Malvern, 
Malvern UK).  Citrate coated 20 nm AgNPs were found to have a hydrodynamic size of 19.13 nm 
which increased to 62.1 nm when a PC consisting of HDL formed on their surface (Table 3.1).  
Addition of HDL to AgNPs resulted in a decrease in AgNP surface charge (due to displacement 
of citrate groups) but increased hydrodynamic size as expected (Table 3.1). The size and spherical 
shape of AgNPs was confirmed through TEM imaging (Figure 3.1A). Enhanced darkfield 
hyperspectral microscopy was utilized to evaluate changes in the spectrum of AgNPs indicative of 
HDL PC formation.  Hyperspectral images of AgNPs (Figure 3.1B) and AgNPs with an HDL PC 
(Figure 3.1C) were collected.  Analysis of the mean spectrums generated from these particles 
demonstrated a red shift or shift to the right of the AgNP spectrum following association with HDL 
(Figure 3.1D) concurring with our previous results (Shannahan et al., 2014).  This red shift is 
indicative of PC formation. 
In Vitro Uptake of Silver Nanoparticles by Macrophages 
AgNP internalization by macrophages was assessed by a variety of methods including ICP-
MS, flow cytometry, and enhanced dark field hyperspectral microscopy.  All experiments utilized 
a time point of 2 h and a AgNP concentration of 50 ug/ml.  These parameters for the evaluation of 
uptake were selected based on preliminary experimentation which, demonstrated macrophage 
uptake of AgNPs had > 85% of cells viability up to 6 h with exposure to AgNPs at concentrations 
of 0, 6.25, 12.5, 25, or 50 μg/ml  (Figure 3.2A and 3.2B). AgNP internalization was quantitatively 
measured through the use of ICP-MS. As expected RAW cell uptake of samples exposed to 50 
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μg/ml of AgNPs for 2 h had higher silver content compared to control samples (Figure 3.2C). 
Coating of particles with HDL led to a significant increase in AgNP uptake compared to uncoated 
AgNPs (Figure 3.2C). To assess the role of SR-B1, cells were pretreated with Blt2 at 50 uM for 
30 min before AgNP exposure. Pretreatment with Blt2 resulted in a significant decrease in the 
internalization of AgNPs (Figure 3.2C). Macrophage uptake of AgNPs was further confirmed by 
flow cytometry via alterations in side scatter shift (SSC).  Alterations in cellular SSC equate to 
changes in cellular granulation which is indicative of macrophage uptake of AgNPs (Suzuki et al., 
2007). Macrophages that were exposed to 50 μg/ml of AgNPs + HDL for 2 h had a greater shift in 
SSC compared to control samples demonstrating increased uptake as observed with ICP-MS 
(Figure 3.2D). Pretreatment with Blt2 at 50 uM for 30 min before AgNP exposure resulted in a 
significant decrease in SSC of both the AgNP and AgNPs + HDL groups (Figure 3.2D). Finally, 
Blt2 pretreatment alone was not found to cause changes in SSC and appeared similar to control 
samples (Figure 3.2D). 
Lastly, cellular uptake was qualitatively assessed through enhanced dark field 
hyperspectral imaging of RAW cells following a 2 h exposure to AgNPs. Macrophages exposed 
to AgNPs and AgNPs coated with HDL demonstrated the presence of NPs within and on the 
surface of cells (Figure 3.3B & 3.3D). Pretreatment with Blt2 at 50 uM for 30 min before exposure 
resulted in decreased AgNP uptake (Figure 3.3C & 3.3E). To confirm the presence of AgNPs in 
macrophages, the spectral profile of the AgNPs as shown in Figure 1 was mapped back to the 
exposed cells.  Pixels that matched the AgNPs were highlighted in red (Figure 3.3, left panel) thus 
confirming the presence of AgNPs within the macrophages.  Samples treated with HDL only or 
Blt2 alone did not show altered cellular morphology or the presence of particles (data not shown). 
In Vitro Macrophage Activation by Silver Nanoparticles 
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PCR array analysis of BMDMs revealed that Tnf-α, Osm, Ccl4, Il17f, Ccl7, and Ccl2 were 
up-regulated, whereas Il16 was found to be down-regulated 2 hrs following AgNP exposure (Table 
3.2).  The inflammatory cytokine OSM was found to be highly induced following AgNP exposure 
and was selected as a novel marker of macrophage activation for subsequent studies.  Further OSM 
was selected due to the high statistical significance compared to control cells versus TNF-α for 
example. 
Oncostatin M protein levels were evaluated following AgNP exposure by ELISA (Figure 
3.4A). Cells were pretreated with media or with Blt2 at a concentration of 50 μM for 30 min before 
a 24 h exposure to AgNP at 50 μg/ml in serum-free media. OSM protein levels significantly 
increased following AgNP exposure (Figure 3.4A). Further, exposure to HDL coated AgNPs 
caused a significant increase in OSM production compared to cells exposed to uncoated AgNPs 
(Figure 3.4A). Pretreatment with Blt2 was found to significantly decrease macrophage OSM 
production in response to both AgNP and AgNPs + HDL exposure (Figure 3.4A). 
Macrophage activation was further evaluated by measuring the expression of the 
macrophage surface marker CD86 by flow cytometry following exposure to 50 μg/ml of AgNPs 
for 2h. Exposure to AgNPs and coated AgNP with HDL caused a significant increase in CD86 
expression compared to control cells (Figure 3.4B).  To evaluate the role of SR-B1, cells were 
pretreated with Blt2 for 30 min prior to AgNP exposure, which was found to decrease AgNP-
induced expression of CD86 to control levels (Figure 3.4B). Furthermore, pretreatment with Blt2 
caused a significant decrease in CD86 expression in cells exposed to AgNP coated HDL compared 
to cells exposed to AgNPs coated with HDL without Blt2 pretreatment (Figure 3.4B). 
In Vivo Uptake of Silver Nanoparticles by Macrophages 
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To investigate the mechanism of AgNP cellular uptake in a physiological system, an in 
vivo experiment was performed using C57BL/6 and SR-B1−/− mice.  C57BL/6 mice were 
pretreated with 50 μl of PBS or PBS with Blt2 at 250 μg/kg of body weight for 30 min followed 
by AgNP exposure at a concentration of 2 mg/kg body weight.  At 2 h post-exposure 
bronchoalveolar lavage fluid (BALF) was collected and macrophage uptake was qualitatively 
determined by enhanced dark field microscopy. Macrophages from C57BL/6 mice demonstrated 
higher particle uptake compared to C57BL/6 mice pretreated with Blt2 (Figure 3.5).   SR-B1-/- 
mice also demonstrated a reduction in macrophage uptake of AgNPs further supporting the role of 
SR-B1 mediated internalization (Figure 3.5).  Lastly, the presence of AgNPs was again confirmed 
by hyperspectral mapping and highlighted in red as described above (Figure 3.5, left panel). 
In Vivo Assessment of Pulmonary Inflammation 
To investigate the role of SR-B1 in pulmonary inflammation in vivo, AgNPs were instilled 
in the lungs of C57BL/6J and SR-B1−/− mice.  In addition, a subset of C57BL/6J mice were 
pretreated with 50 μl of PBS or PBS with Blt2 at 250 μg/kg of body weight for 30 min prior to 
AgNP exposure.  At 24 h post exposure, BALF was collected and differential cell counts were 
assessed to understand the in vivo inflammatory response. BALF cell counts revealed a significant 
increase in total cells in C57BL/6J and SR-B1−/− mice that were exposed to AgNPs compared to 
control mice. However, mice pretreated with Blt2 and exposed to AgNPs showed significant 
reduction in total cell counts compared to C57BL/6J mice that were exposed to AgNPs. Further, 
SR-B1 -/- mice exposed to AgNPs demonstrated a reduction in BALF total cell counts compared 
to wild type. Lung macrophage numbers were the highest in C57BL/6J mice exposed to AgNPs 
whereas pretreated mice with Blt2 and exposed to AgNPs had a reduction in macrophages similar 
to control mice. Furthermore, we found a significant increase in neutrophilic influx in C57BL/6 
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mice treated with AgNPs that was significantly reduced in mice pretreated with Blt2 (Figure 3.6).  
Further supporting the role of SR-B1 in macrophage activation, SR-B1-/- mice demonstrated a 
reduction in neutrophil recruitment following AgNP exposure (Figure 3.6). Finally, mice treated 




Macrophages form the first line of immune defense against invading pathogens and foreign 
particles and are likely to interact with and facilitate NP clearance.  Currently there are limitations 
to our knowledge regarding how immune cells such as macrophages recognize NPs and the 
subsequent induction of inflammation. Recent studies have reported that different types of immune 
cells including mast cells and macrophages can interact with NPs resulting in an inflammatory 
response, oxidative stress, and pathology (Singh and Ramarao, 2012, Katwa et al., 2012, Wingard 
et al., 2011). The interactions that occur between NPs and cells can be influenced by a variety of 
factors such as the physicochemical properties of the NP and the characteristics of the cell type 
including cell surface receptor expression (Aldossari et al., 2015).  Our current study investigated 
the role of SR-B1 in the recognition, uptake, and activation of macrophages by AgNPs. Through 
the use of pharmacological inhibition of SR-B1 and SR-B1 deficient mice, we demonstrated that 
SR-B1 contributes to macrophage uptake and activation by AgNPs. Further, by coating AgNPs 
with HDL, a known ligand of SR-B1, we were able to enhance macrophage uptake and activation. 
Taken together these in vivo and in vitro findings support the role of SR-B1 in the immune response 
that is induced by AgNP exposure. 
Macrophages express a wide range of cell surface receptors including a variety of scavenger 
receptors.  Specifically, SR-B1 is known to interact with negatively charged particles and mediates 
the uptake of lipoproteins such as HDL.  In our current study we demonstrated that 
pharmacological inhibition of SR-B1 or use of a knockout mouse model reduced AgNP uptake by 
macrophages.  This finding suggests that drug delivery systems, which utilize NPs that are not 
readily recognized by the SR-B1 receptor, may be able to more efficiently evade the immune 
system thereby increasing the amount of delivered drug to target sites.  Overall macrophage uptake 
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and responses to AgNPs were not completely blocked through the inhibition of SR-B1.  Therefore 
it is likely that other cell surface receptors such as scavenger receptor A, Toll-like receptors and 
others contribute to macrophage uptake and responses.  However, our study does support a 
significant role for SR-B1 in the uptake of AgNPs by macrophages and their inflammatory 
response. 
Due to the role of SR-B1 in lipoprotein uptake and importantly that we have demonstrated the 
preferential association of lipoproteins with AgNPs following incubation in cell culture media, we 
decided to examine the influence of an HDL PC on macrophage responses to AgNPs (Shannahan 
et al., 2013a, Shannahan et al., 2013b). The formation of this PC is dependent on the 
physicochemical properties of the NP as well as the physiological environment.  Addition of the 
PC influences the biological impact of the NP through modifying biodistribution, cellular uptake, 
activity, and toxicity (Podila and Brown, 2013). Through modifications in the identity of the PC it 
may be possible to precisely target NPs to specific cells and/or receptors. Binding of HDL with 
AgNPs was found to alter the physicochemical properties of AgNPs.  Specifically, association of 
HDL with AgNPs increased their hydrodynamic size while decreasing surface charge. In our 
current study, upon coating AgNPs with HDL, macrophage uptake was increased. This increase 
in uptake was not charge driven as addition of HDL was found to reduce surface charge suggesting 
that the mechanism of this increased uptake was mediated through receptor recognition of HDL. 
Since HDL is a ligand for SR-B1 it is likely that an HDL PC increased the affinity of AgNPs for 
the SR-B1 receptor allowing for enhanced internalization.  This finding also demonstrates that the 
recognition of NPs by immune cells is based to a degree on the identity of the PC. Further these 
findings suggest that individuals with serum rich in lipoproteins may have increased immune 
responses to AgNP exposure due to enhanced macrophage uptake. Additional studies have 
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demonstrated that addition of a complex corona (consisting of multiple proteins) often results in 
decreased uptake by cells (Monteiro-Riviere et al., 2013), however, our current study demonstrates 
increased uptake following association of AgNPs with an individual lipoprotein, HDL. It is likely 
that decreases in uptake caused by the addition of complex PC are merely a surface charge driven 
effect.  When NPs however are coated with a receptor-specific protein this decrease in surface 
charge-driven uptake can be overcome through enhanced receptor affinity. Further this study 
demonstrates that production of NPs, which are coated with specific proteins or preferentially bind 
proteins in a biological system can be used to more efficiently target NPs. 
Activation of macrophages following AgNP exposure led to an up-regulation of numerous 
chemokines and cytokines as it is indicated by our PCR array data. OSM was one of the most 
significantly upregulated genes and is a member of the gp130 cytokine family, which is secreted 
by several different immune cells (Kishimoto et al., 1995). The gp130 cytokine family has been 
reported to modulate cellular differentiation, immune, and inflammatory cell networks (Kishimoto 
et al., 1995). In addition, OSM has been reported to be upregulated following different types of 
particulate matter exposure (Erdely et al., 2012, Fujii et al., 2002). In our current study, OSM was 
found to be upregulated following AgNP exposure. This finding suggests that OSM may play a 
role in mediating AgNP-induced immune response, inflammation, and inflammatory cell 
recruitment at the site of exposure. Another marker of macrophage activation we utilized in our 
study was CD86, a costimulatory molecule, which has been studied for its role in immune 
responses (Orabona et al., 2004).  CD86 is known to cause the induction of different inflammatory 
cytokines such as IL-6 via NF- κB signaling (Orabona et al., 2004). In addition, blockade or 
deletion of CD86 has been shown to reduce mortality and decrease pro-inflammatory cytokine 
production in promicrobial sepsis (Nolan et al., 2008). Furthermore, CD86 was found to be up-
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regulated in immune cells following exposure to different types of NPs (Roy et al., 2014, Zhu et 
al., 2014). In our current study, we demonstrated that CD86 expression was up-regulated following 
AgNP exposure. This result indicates the induction of an inflammatory response through CD86 
signaling which may lead to the production of pro-inflammatory cytokines via NF- κB signaling. 
In this study, a variety of techniques were used to evaluate macrophage uptake of AgNPs 
including ICP-MS, changes in side scatter (SSC) by flow cytometry, and hyperspectral dark field 
microscopy.  These methods were found to be in agreement demonstrating modifications in AgNP 
uptake via the use of SR-B1 inhibition as well as the addition of an SR-B1 ligand, HDL, to the 
AgNP surface. In vitro experimentation demonstrated the rapid (2 h) interaction and immune 
response following AgNP exposure.  Induction of in vitro cellular uptake and activation in this 
study was confirmed in vivo by using SR-B1 knock out mice and mice pretreated with a SR-B1 
inhibitor. Oropharyngeal instillation was utilized in our studies because this route of exposure 
allowed for the quickest assessment of a macrophage population in vivo for the mechanistic 
evaluation AgNP uptake and activation.  In summary our in vivo findings confirmed our in vitro 
studies demonstrating a role for SR-B1 in macrophage uptake and activation. 
Conclusion 
In summary our current study demonstrates that SR-B1 partially mediates cellular uptake and 
activation following AgNP exposure. These findings have implications in understanding 
mechanisms of AgNP toxicity. In addition, our results demonstrate that association of 
biomolecules with NPs can influence not only their physicochemical properties but also their 
cellular distribution and effect.  Further investigation of signaling mechanism pathways is needed 
for more understanding of AgNP toxicity.  In conclusion our findings demonstrate that AgNPs can 
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20 nm AgNPs 19.13 ± 1.95 -35 
20 nm AgNPs + HDL 62.10 ± 1.79 -8 
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Figure 3.1 Transmission electron microscopy (TEM) and Hyperspectral Enhanced Darkfield 
Images of AgNPs and AgNPs + HDL 
A) Representative TEM images demonstrating AgNP shape and size. B) Hyperspectral enhanced 
dark field image of AgNPs. C) Hyperspectral enhanced dark field image of AgNP + HDL. D) 
Comparison of mean spectrums of AgNP (Black) and AgNP + HDL (Red) demonstrating a red 
shift in spectra indicative of association of HDL with the surface of AgNPs.  Numbers above 






Figure 3.2 Evaluation of AgNPs Cytotoxicity and Uptake by Macrophages 
A) Cytotoxicity in mouse macrophages RAW264.7 (RAW) at 3 h following exposure to AgNP, 
AgNP + HDL.  Cells were exposed to (0, 6.25, 12.5, 25, or 50 µg/ml) of AgNPs or AgNPs + HDL 
in serum-free media. B) Cytotoxicity in RAW cells at 6 h following exposure to AgNP, AgNP + 
HDL. Cells were exposed to (0, 6.25, 12.5, 25, or 50 µg/ml) of AgNPs or AgNPs + HDL in serum-
free media. C) Total macrophage uptake of AgNPs as measured by inductively coupled plasma 
mass spectrometry (ICP-MS). RAW cells were exposed to 50 μg/ml AgNPs for 2 h with or without 
pretreatment with the scavenger receptor B1 (SR-B1) inhibitor, Blt2 (50 uM). D) Measurement of 
macrophage uptake of AgNPs assessed through alterations in side scatter (SSC) shift using flow 
cytometry measurement of 5x103 events. RAW cells were exposed to 50 μg/ml AgNPs for 2 h 
with or without pretreatment with the scavenger receptor B1 (SR-B1) inhibitor, Blt2 (50 uM). 
Values are expressed as mean ± SEM (n=3/group). *Significant difference from control (p ≤ 0.05). 
#Significant difference of Blt2 pretreated group compared to Blt2 untreated group (p ≤ 0.05). 
$Significant difference between the AgNPs + HDL exposed group and the AgNP exposed group 
(p ≤0.05).  
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Figure 3.3 Darkfield Imaging and Hyperspectral Mapping of RAW cells Following AgNPs 
and AgNPs + HDL Exposure 
A) Darkfield image of control mouse macrophages RAW264.7 (RAW) (left panel), identification 
of AgNPs through hyperspectral mapping in RAW cells (right panel). B) AgNP uptake by RAW 
cells (left panel), hyperspectral mapping of AgNPs in RAW cells (right panel). C) RAW cells 
pretreated with scavenger receptor B1 (SR-B1) inhibitor (Blt2) then exposed to AgNPs (left panel), 
hyperspectral mapping of AgNPs (right panel). D) RAW cells exposed to AgNPs + HDL (left 
panel), hyperspectral mapping of AgNPs + HDL (right panel). E) RAW cells pretreated with Blt2 













Figure 3.4 Evaluation of Oncostain M (OSM) and CD86 Expression Following AgNPs and 
AgNPs + HDL Exposure 
A) Oncostatin M (OSM) supernatant protein levels 24 h post exposure. Mouse macrophages 
RAW264.7 (RAW) were exposed to 50 μg/ml of AgNPs for 24 h with or without pretreatment 
with scavenger receptor B1 (SR-B1) inhibitor, Blt2 (50uM). B) Mean fluorescence of CD86 
expression measured by flow cytometry of 5x103 events. RAW cells exposed to 50 μg/ml of 
AgNPs for 6 h with or without pretreatment with scavenger receptor B1 (SR-B1) inhibitor, Blt2 
(50uM). Values are expressed as mean ± SEM (n=3/group). *Significant difference from control 
(p ≤ 0.05). #Significant difference of Blt2 pretreated group compared to Blt2 untreated group (p ≤ 
0.05). $Significant difference between the AgNPs + HDL exposed group compared to the AgNPs 







Figure 3.5 Evaluation Role of Scavenger Receptor B1 (SR-B1) in AgNPs uptake Following 
Oropharyngeal Aspiration 
Macrophage uptake of AgNPs was evaluated in vivo using C57BL/6 and SR-B1-/- mice.  C57BL/6J 
mice were pretreated with either PBS or Blt2 (250 µg/kg of body weight) for 30 min and then 
exposed to AgNPs at a concentration of 2 mg/kg body weight via oropharyngeal aspiration.  
Bronchoalveolar lavage fluid was collected 2 h post-exposure and macrophage uptake was 
qualitatively determined by enhanced dark field microscopy.  Spectral mapping was utilized to 
positively identify pixels matching the spectrum of AgNPs.  These pixels are shown in the right 
columns in red.  A) Representative dark field image of macrophages collected from C57BL/6 mice 
exposed to AgNPs (left panel), and spectral mapping of AgNPs (right panel). B) Representative 
dark field image of macrophages collected from C57BL/6J mice pretreated with Blt2 and then 
exposed to AgNPs (left panel), and spectral mapping of AgNPs (right panel). C) Representative 
dark field image of macrophages collected from SR-B1-/- mice exposed to AgNPs (left panel), and 










Figure 3.6 Role of Scavenger Receptor B1 (SR-B1) in AgNPs-Induced Inflammation in Mice 
Bronchoalveolar lavage fluid (BALF) differential cell counts from C57BL/6 or SR-B1-/- mice 
exposed to AgNPs.  C57BL/6J mice were pretreated with either PBS or Blt2 (250 µg/kg of body 
weight) for 30 min prior to AgNP exposure.  BALF was collected 24 h post-exposure to AgNPs. 
Values are expressed as mean ± SEM (n=3/group). *Significant difference from control (p ≤ 0.05). 






Chapter 4: General Discussion 
The present study was conducted to evaluate the influence of physicochemical properties 
of AgNPs on uptake and activation mast cells and macrophages and the role of SR-B1 following 
exposure to AgNPs.  
In Aim 1, we evaluated the uptake of AgNPs uptake by mast cells and macrophages. Mast 
cells have been reported to internalize different types of NPs such as silicon dioxide (SiO2) and 
titanium dioxide (TiO2) which were found to be localized in the secretory granules (Maurer-Jones 
et al., 2010). NP internalization by mast cells can inhibit mast cell activation and degranulation as 
has been reported with fullerene exposure or can induce mast cell activation and degranulation as 
reported with gold NP exposure (Ryan et al., 2007, Huang et al., 2009, Marquis et al., 2009). Gold 
NPs were found to induce mast cell degranulation that was dependent on size, exposure time, and 
concentration (Marquis et al., 2009, Huang et al., 2009). Previous studies demonstrated the ability 
of the mast cell-NP interaction to mediate activation or suppression of the mast cell, however, 
limited data are available for mast cell interaction with AgNPs and the role of physicochemical 
characteristics of AgNPs. 
In this study mast cells were exposed to AgNPs with different physicochemical 
characteristics including 20 and 110 nm spherical AgNPs either suspended in citrate (C20 and 
C110), or polyvinylpyrrolidone (PVP) (P20 and P110).  In addition, two different sizes of 
nanoplates with optical resonance peaks at specific wavelengths of 550 nm and 850 nm suspended 
in PVP (P550 and P850), or Ag nanowires that were up to 2 μm long suspended in PVP (Figure 
2.1) were utilized. All types of AgNPs were found to be internalized by mast cells in varying 
amounts based on their physicochemical differences (Figure 2.2 and 2.3). AgNPs suspended in 
citrate including C20 and C110 were found to have a more highly negative zeta potential compared 
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to spherical AgNPs that were suspended in PVP. AgNPs that were suspended in PVP were found 
to be more associated to cells compared to citrate suspended particles of the same size and shape 
(Table 2.1). This is likely due to PVP acting as stabilizer for AgNPs and being oxidized resulting 
in binding with biomolecules (Podila et al., 2012). Such an observation suggests that uptake is not 
completely driven by charge but also by the type of surface coating. Interestingly, AgNPs with the 
same coating agent and similar surface charge including P110, P550, and Ag nanowires were 
found to have varying internalization amounts which demonstrates that other NP properties 
including size and/or shape can influence their cellular uptake. These observations concur with 
other previous results that reported the influence of size and shape of NPs on their cellular uptake 
(Miethling-Graff et al., 2014). Furthermore, AgNPs including P550 and P850 that have the same 
surface coating and shape but differ in their size were found to be taken up differently where P850 
had greater internalization by cells. Taken together, internalization of tested AgNPs by mast cells 
is a complex process that depends on a combination of different physicochemical factors. 
Macrophages also can interact with NPs resulting in cellular activation and induction of an 
inflammatory response (Singh and Ramarao, 2012). Our current study tested macrophage uptake 
of C20 and C20 coated with HDL. AgNPs coated with HDL were used to investigate the role of 
SR-B1 in uptake since this receptor recognizes lipoprotein molecules. The physicochemical 
properties of AgNPs such as size and zeta potential were found to be affected after PC formation 
(Table 3.1 and Figure 3.1). AgNP internalization was demonstrated by different techniques 
including ICP-MS, flow cytometry, and hyperspectral dark field microscopy (Figure 3.2). In 
addition, alveolar macrophages were found to take up and internalize AgNPs in an in vivo study 
(Figure 3.3). AgNPs were found to be taken up by macrophages in in vitro experiments, whereas, 
HDL coated NPs had more internalization by macrophages demonstrating a potential role for the 
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SR-B1.  The HDL coated AgNPs were found to have an increase in size and a decrease in their 
surface charge. The previous finding suggests the NP uptake was driven by changing AgNP 
identity which resulted in increased receptor recognition of AgNPs coated with HDL. These 
findings support a significant role of SR-B1 in the internalization of AgNPs by macrophages. 
Further, the higher uptake of HDL coated AgNPs suggests that individuals with serum rich in 
lipoproteins may display an increased immune response to AgNPs due to an increase in NP uptake 
by immune cells because of association of AgNPs with lipoprotein molecules. These findings 
suggest that the production of NPs, which are coated with key proteins preferentially bind receptors 
in a biological system and could potentially be used for improved tissue/cell targeting for NPs. 
The focus of aim 2 was to evaluate mast cell and macrophage activation following AgNP 
exposure. Mast cells play an important role in innate immunity, host defense and allergic disease 
and can be found in most tissue types (Brown et al., 2008a). Mast cells acting through different 
receptors such as TLRs and SRs can recognize pathogens and foreign molecules resulting in 
inflammatory responses including degranulation and release of pro-inflammatory cytokines 
(Brown et al., 2007, Medic et al., 2008, McCurdy et al., 2003). Mast cells have been reported to 
play a role in the inflammatory response following NPs exposure such as MWCNTs (Wingard et 
al., 2011, Katwa et al., 2012). Limited data are available, however, that evaluate the role of 
physicochemical properties of AgNPs on mast cell activation. 
Our current study investigated the direct interactions of AgNPs that have different 
physicochemical characteristics on mast cell activation and degranulation. While C110 and P110 
did not induce mast degranulation, all other types of AgNPs induced mast cell degranulation 
(Figure 2.4). Although P550 and P850 have a similar shape and surface charge, P550 with a smaller 
size was found to induce more mast cell degranulation compared to P850. Furthermore, P110 
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shares the same surface charge and coating with Ag nanowires and P550, however, it did not 
induce mast cell degranulation. Interestingly, Ag nanowires displayed reduced cellular uptake, but 
induced mast cell degranulation which is likely due to the high aspect ratio particles. Similar NPs 
with high aspect ratio have been reported to induce immune cell activation (Sunshine et al., 2014, 
Hamilton et al., 2013, Li et al., 2013a, Sharma et al., 2010). These findings demonstrated the effect 
of size and possibly AgNP shape in mast cell degranulation which is likely mediated through cell 
surface receptor recognition. These findings are consistent with other reports that mast cells can 
interact differently based on different size and shape characteristics of the same nanomaterials 
such as CNTs (Huang et al., 2009, Katwa et al., 2012, Ryan et al., 2007, Umemoto et al., 2014). 
Our current findings demonstrated mast cell degranulation is not entirely dependent on 
AgNPs internalization as C110 and P110 were found to be taken up by mast cells but did not 
induce mast cell degranulation. In addition, C20 and P20 induced a similar level of mast cell 
degranulation although the P20 AgNPs were found to be more heavily internalized by mast cells 
compared to C20. Finally, our current study suggests that lysosome-associated membrane protein 
2 (Lamp2) should be considered as a candidate biomarker for identifying mast cell activation 
following AgNP exposure since we found Lamp2 upregulation correlated well with mast cell 
degranulation data (Figure 2.5).  These findings of different responses by mast cells are consistent 
with other reports that mast cells can be induced or suppressed following NP exposure (Dellinger 
et al., 2010, Ryan et al., 2007, Umemoto et al., 2014). In addition, these findings demonstrated a 
direct interaction of mast cells with AgNPs that can induce mast cell degranulation which is not 
entirely driven by cellular internalization, therefore, this interaction can possibly occur in vivo and 
result in induction or promotion of allergic disease. 
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Activation of mast cells by NPs including MWCNTs and cerium oxide resulted in the 
release of cytokines such as osteopontin as previously reported by our laboratory (Katwa et al., 
2012, Wingard et al., 2011). Osteopontin is a secreted phosphoglycoprotein produced by different 
types of cells and can be used as a risk predictor of various diseases such as cancer such as 
mesothelioma that developed following asbestos exposure (Berezin and Kremzer, 2013, Pass and 
Carbone, 2009, Yang et al., 2008). In our current study, we found osteopontin upregulation in mast 
cells following exposure to all selected types of AgNPs (Figure 2.6). The cytokine production by 
mast cells even in the absence of or limited degranulation supports similar previous findings by 
our laboratory which demonstrated that mast cell activation following silica exposure resulted in 
cytokine production with limited cell degranulation (Brown et al., 2007). This demonstrated that 
mast cell degranulation may involve different cell signaling pathways and that idea is further 
supported by a recent study conducted in our laboratory which demonstrated AgNP-directed mast 
cell degranulation involves activation of PI3K, PLCγ and an increase in intracellular calcium levels 
(Alsaleh et al., 2016). 
Macrophage activation can be induced by NP exposure which results in upregulation of 
chemokine and cytokine expression, mitochondrial damage, and apoptosis (Singh and Ramarao, 
2012). In our current study, we found upregulation of different cytokines and chemokines 
following exposure to AgNPs. Oncostatin M was one of the most significantly upregulated genes 
(Table 3.2). Oncostatin M is a member of the gp130 cytokine family and can be secreted by 
different types of immune cells (Kishimoto et al., 1995). The gp130 cytokine family has been 
reported to be involved in the modulation of different immune and inflammatory cell networks 
(Kishimoto et al., 1995). Specifically, oncostatin M has been reported to be upregulated in different 
types of cells such as macrophages and epithelial cells following particulate matter exposure 
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(Erdely et al., 2012, Fujii et al., 2002). In our current study, we found upregulation of the oncostatin 
M gene and protein levels which supports its involvement in the inflammation and inflammatory 
cell recruitment immune response induced by AgNPs exposure(Figure 3.4A). Furthermore, HDL 
coated AgNPs were found to induce higher levels of oncostatin M which indicates a potential role 
for the PC in induction of inflammatory response by macrophages. 
The macrophage activation marker CD86 was found to be upregulated in our study. CD86 
is a co-stimulatory molecule that has been studied for its role in immune responses (Orabona et 
al., 2004). In addition, CD86 is known to induce inflammatory cytokine production such as IL-6 
through NF-κB signaling (Orabona et al., 2004). In our current study, we found CD86 expression 
was upregulated following AgNP exposure, whereas, AgNPs coated with HDL induced higher 
expression compared to exposure to AgNPs with no HDL coating thereby demonstrating a role for 
the PC in the inflammatory response induced by macrophages following NP exposure (Figure 
3.4B).  This finding concurs with other reports in which CD86 was found to be upregulated in 
immune cells following exposure to different types of NPs (Roy et al., 2014, Zhu et al., 2014). 
These findings suggest that AgNPs can induce macrophage activation through increasing CD86 
signaling resulting in production of pro-inflammatory cytokines through the NF-κB signaling 
pathway. 
In aim 3 we established a potential role of the scavenger receptor B1 (SR-B1) in mast cell 
and macrophage uptake and activation following AgNP exposure. SR-B1 is a multi-ligand receptor 
that preferentially interacts and facilitates uptake of lipoprotein molecules such as HDL and other 
negatively charged molecules.  In addition, SR-B1 can interact with pathogens and NPs 
(Landschulz et al., 1996, Eyre et al., 2010, Mooberry et al., 2010). 
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In this current study, all different types of selected AgNPs were found to have a negative 
charge therefore they were hypothesized to interact with SR-B1. In mast cells, pretreatment with 
the specific SR-B1 inhibitor Blt2 was found to reduce the uptake of P20, P110, C110, and P850 
AgNPs while C20, P550, and Ag nanowires found to be unaffected (Figure 2.3). This suggests that 
SR-B1 recognition of AgNPs does not appear to be dependent on NP surface charge due to the 
range of surface charge carried by each type of AgNPs. Mast cell degranulation was found to be 
reduced in pretreated cells with Blt2 following exposure to P20, C20, P550, and Ag nanowires 
(Figure 2.4). Inhibition of SR-B1 was found to reduce mast cell degranulation to control levels in 
cells exposed to P20 or C20. This suggests that P20 and C20 AgNPs induce mast cell degranulation 
via SR-B1 recognition whereas P550 AgNPs and Ag nanowires induce mast cell degranulation 
with possible contribution of other cell surface receptors. 
Overall, by using the SR-B1 inhibitor we demonstrated that SR-B1 can modulate mast cell 
uptake of and activation by AgNPs following exposure. Our findings suggest that different 
characteristics of AgNPs may have an impact on designing safer NPs that have no, or at least very 
little, interaction with scavenger receptors to avoid activation of the inflammatory immune 
response by mast cells. Furthermore, our current study also demonstrates a role for SR-B1 in 
osteopontin release (Figure 2.6). Pretreatment with the SR-B1 inhibitor resulted in a reduction in 
the release of osteopontin which suggests AgNPs can induce production of mast cell cytokines and 
contribute in the mast cell inflammatory response in presence or absence of cell degranulation. 
Finally, mast cells can be activated through signals from surface receptors such as SR-B1, 
FcεRI, or c-Kit which resulted in increased calcium flux, tyrosine kinase phosphorylation, and 
eventually degranulation of mast cells (Canton et al., 2013, Zhu et al., 2009). Inhibition of tyrosine 
kinase phosphorylation by a therapeutic agent such as imatinib leads to a reduction in mast cell 
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degranulation. In this study, we determined that C20 AgNPs-induced mast cell degranulation can 
be inhibited by pretreatment with imatinib (Figure 2.7). This suggests AgNP-induced mast cell 
degranulation can be inhibited therapeutically. In addition, this finding suggests that mast cell 
degranulation depends on the physicochemical properties of AgNPs which affect downstream cell 
signaling events such as activation of PI3K, PLCγ and an increase in intracellular calcium levels 
(Alsaleh et al., 2016).  
Macrophage scavenger receptors have been reported to interact with NPs and influence NP 
internalization, cellular trafficking, and pro-inflammatory cytokine secretion (Orr et al., 2011). In 
our current study, we demonstrated a role for SR-B1 where AgNP uptake by macrophages was 
found to be reduced in cells pretreated with a SR-B1 inhibitor, while uptake of HDL coated AgNPs 
was reduced to control level in cells pretreated with Blt2 (Figure 3.2C&D and Figure 3.3).  The 
partial inhibition of AgNP uptake through SR-B1 suggests that other cell surface receptors may 
contribute to AgNP uptake. In addition, uptake of AgNPs was found to be reduced in alveolar 
macrophages in animal studies using SR-B1 knockout mice or wild type mice pretreated with Blt2 
(Figure 3.5).  These findings suggest that utilizing NPs in therapeutics that are not recognized by 
SR-B1 may be able to avoid immune system activation and cellular uptake and thereby increase 
the amount of delivered drugs to target tissues. 
The role of SR-B1 in macrophage activation was also supported by studies that 
demonstrated that the inhibition of SR-B1 resulted in a reduction in oncostatin M and CD86 
expression following AgNPs exposure (Figure 3.4). In addition, formation of PC resulted in more 
inhibition by Blt2 of oncostatin M and CD86 expression compared to AgNPs with no HDL 
coating. This finding demonstrates the role of SR-B1 in lipoprotein uptake which supports the idea 
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that formation of PC could increase AgNP binding affinity and have an effect on biodistribution, 
cellular uptake, and cellular toxicity as it has been reported before (Podila and Brown, 2013). 
Finally, the role of SR-B1 in the inflammatory response induced by AgNPs was confirmed 
in an in vivo study using SR-B1 knockout mice and mice pretreated with a SR-B1 inhibitor (Figure 
3.6). We found an increase in total cell count and neutrophils in bronchoalveolar lavage fluid in 
wild type mice compared to SR-B1 knockout mice and mice pretreated with Blt2. These findings 
confirmed a role of SR-B1 in the inflammatory response following AgNP exposure. 
Overall the data generated from this study has significantly contributed to our 
understanding of the influence of physicochemical properties of AgNPs on mast cell and 
macrophage activation. In addition, this study investigated role of SR-B1 in AgNP interactions 
with mast cells or macrophages. The physicochemical properties of AgNPs contributed to different 
immune responses, whereas, SR-B1 was found to partially mediate the interaction of AgNPs with 
immune cells. Future research is needed to understand and define the cell signaling pathways 
involved to gain additional insight into the mechanisms that underlie AgNP toxicity. In conclusion, 
our findings demonstrate that AgNPs can be formulated and modified to avoid or reduce their 
adverse effects and to increase their efficiency for biomedical applications. 
Future studies 
The interaction of NPs and physiological systems following exposure to NPs led to an 
increased effort to carry out research aimed to understand the molecular interactions and cellular 
uptake pathways such as scavenger receptors, and complement receptors that may participate in 
the toxicity associated with these substances (Patel et al., 2010, Yang et al., 2010a, Sahay et al., 
2010). Differences in genetic background can affect this cellular-NP interaction through modifying 
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the expression of receptors involved in this interaction or by affecting TH1-TH2 and M1-M2 status 
(Murphy and Reiner, 2002). The immune response following exposure to NPs can be shifted 
towards a TH1 or TH2 response mediated by T helper cells leading to the production of specific 
cytokines and mediators to each response (Murphy and Reiner, 2002). The TH1 response can 
polarize macrophages toward the M1 phenotype while TH2 response has tendency to polarize 
macrophages toward the M2 phenotype (Mills et al., 2000, Gordon and Martinez, 2010). While 
the M1 and M2 phenotypes express different types of receptors, they can also share same receptors 
but with different levels of expression which can affect the level of cellular-NP interaction and 
clearance (Chinetti-Gbaguidi et al., 2011). Therefore, future studies should examine the effects of 
M1 versus M2 polarization on the response to NP exposure. 
It has been reported that mice with different genetic backgrounds show different effects on 
NP clearance (Jones et al., 2013). The previous study reported that TH1-biased strains such as 
C57BL/6 have slow NP clearance with high NP blood concentration while TH2-biased strains such 
as BALB/c showed rapid NP clearance and that was mediated by immune cells including 
monocytes, macrophages, and granulocytes (Jones et al., 2013). 
Another study that investigated pulmonary toxicity induced by AgNPs in different rat 
strains reported that the genetic background produced different inflammatory responses following 
NP exposure (Seiffert et al., 2015). The previous study reported that Brown-Norway rats exposed 
to NPs showed early bronchial hyperresponsiveness and rapid recruitment of neutrophils and 
eosinophils compared to exposed Sprague-Dawley rats (Seiffert et al., 2015). In addition, increased 
cytokine production in the lungs including IL-13 and CCL11 was found in Brown-Norway rats 
compared to Sprague-Dawly rats (Seiffert et al., 2015). The investigators explained the increase 
in inflammatory response in Brown-Norway rats might be due to an increase in TH2 cytokine 
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production such as IL-10 and IL-13 in macrophages isolated from Brown-Norway rats and these 
finding was supported by an increase in IgE levels in bronchoalveolar lavage.  Therefore, AgNPs 
are more likely to induce inflammatory responses and increase eosinophils  in Th2-biased 
asthmatic subjects (Seiffert et al., 2015). 
Based on the previous studies, the genetic background can play an important role in NP 
biodistribution and cellular interaction in different strains of mice and rats. Therefore, future 
studies should include efforts to assess the genetic background in the experimental design to have 
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